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ABSTRACT 
 
RUPNINDER SANDHU: Hypermethylator Phenotype in Human Breast Cancer: Therapeutic 
Target and Mechanism of DNMT3b Regulation  
(Under the direction of William B Coleman, Ph.D.) 
 
 
 A subset of primary breast cancers and breast cancer cell lines express a 
hypermethylation defect characterized by DNMT hyperactivity and DNMT3b 
overexpression. The objectives of this project were (i) to determine if targeting the 
methylome enhances the sensitivity of breast cancer cells to chemotherapy, and (ii) to 
elucidate the molecular mechanism governing the DNMT3b-mediated hypermethylation 
defect in breast cancer.  To address the first objective, hypermethylator breast cancer cell 
lines were treated with demethylating agent (5-aza-2’-deoxycytidine) and/or were subjected 
to RNAi-mediated DNMT3b knockdown (KD), and then tested for sensitivity to doxorubicin 
hydrochloride, paclitaxel, and 5-fluorouracil. The results show that pharmacologic 
demethylating pretreatment sensitizes hypermethylator breast cancer cells to cell killing by 
cytotoxic drugs, and provide proof-of-concept that direct targeting of DNMT3b also 
improves cell kill by these drugs. These findings suggest that targeting the methylome 
improves chemotherapeutic efficacy of cytotoxic drugs against hypermethylator breast 
cancer cells as a function of dose and duration of exposure to demethylating treatment. To 
address the second objective, the expression of microRNAs (miRs) that regulate or are 
predicted to regulate DNMT3b were examined in hypermethylator or non-hypermethylator 
breast cancer cell lines and in primary breast cancers. Hypermethylator cell lines express 
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diminished levels of regulatory miRs compared to non-hypermethylator cell lines. 
Mechanistic studies were conducted to establish the role of miR expression in the 
hypermethylation defect. Antagomir-mediated knockdown of regulatory miRs in non-
hypermethylator cell lines resulted in increased DNMT3b mRNA and forced re-expression of 
regulatory miRs reduced DNMT3b mRNA in hypermethylator cell lines. In primary breast 
cancers, miR expression patterns revealed two distinct subsets among the basal-like subtype. 
Most hypermethylator basal-like cancers exhibit diminished expression of regulatory miRs. 
These findings strongly suggest that diminished expression of multiple regulatory miRs 
contributes to DNMT3b overexpression. Together, these results support the conclusion that 
the molecular mechanism governing the DNMT3b-mediated hypermethylation defect in 
breast cancer cells is the loss of post-transcriptional regulation of DNMT3b by regulatory 
miRs, and that combined epigenetic and cytotoxic treatment will improve the efficacy of 
breast cancer chemotherapy.  
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INTRODUCTION 
 
Breast Cancer Statistics 
 Breast cancer is a disease that is diverse in natural history, response to treatment, and 
patient outcomes.  It remains the most common non-cutaneous female malignancy with an 
estimated 209,060  new cases in 2010 in the United States [1].  Breast cancer-associated 
mortality is second only to lung cancer in the United States among women, with an estimated 
40,230 deaths in 2010 [1].  Breast cancer is also the most commonly diagnosed female 
malignancy worldwide. According to the American Cancer Society (www.cancer.org), 
approximately 1.2 million women worldwide are diagnosed with breast cancer each year. 
The lifetime probability of developing breast cancer in developed countries is 1 in 8 women 
[1]. The incidence of breast cancer as well as the associated mortality rate increases with age 
(Figure 1.1). Women above age 40 accounted for 95% of new cases and 97% of deaths 
associated with breast cancer from 2002-2006 (www.cancer.org). The highest incidence rate 
of 441.9 cases per 100,000 women is observed in women between 75-79 years of age and the 
lowest incidence of 1.4 cases per 100,000 women is observed in women from 20-24 years-
old (www.cancer.org). Reduction in incidence rates observed among women over 80 years of 
age may be an indication of lower rates of screening, cancers detected before 80 years (by 
mammography), and incomplete detection (www.cancer.org). From 2003-2007, the age-
adjusted death rate associated with breast cancer was 24.0 per 100,000 women per year and 
the median age at death due to breast cancer was 68 years of age (www.cancer.org). 1% of 
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these deaths occurred in women below the age of 34 years.  There was an increase in deaths 
with age from age 35 onwards; women between 35 and 44 years of age accounted for 6% of 
the breast cancer deaths, women between 45 and 54 years of age accounted for 15% of the 
deaths and the 20.8% of breast cancer associated deaths were seen in women with ages 
between 55 and 64.  Likewise, women with ages between 65 and 74 accounted for 19.7% of 
the deaths, women with ages between 75 and 84 accounted for 22.6%; and women above 85 
years of age accounted for 15.1% of the breast cancer associated deaths (www.cancer.org). 
 Race/ethnicity plays a major role in the development of breast cancer. In the United 
States, the incidence rate of breast cancer is highest among Caucasian women above the age 
of 45 years. Below age 45, African-American women have the highest incidence of breast 
cancer. Figure 1.2 Incidence of breast cancer among other racial/ethnic groups is lower than 
the incidence among Caucasian and African-American women.  The overall age-adjusted 
incidence rate based on 2004-2008 SEER data was 124 per 100,000 women per year (Table 
1.1). African-American women also have the highest mortality rate associated with breast 
cancer at every age in comparison with Caucasian women and women of other 
races/ethnicities (Table 1.2).  
 Since the late 1980s, there has been significant reduction in deaths related to breast 
cancer. This decline occurred partly due to the advancements in the therapy and partly due to 
improved screening and early diagnosis. Widely implemented screening programs (including 
self-examination and screening mammography) have not only affected the survival rates but 
have also shifted the cancer profile characteristics detected today increasingly towards 
smaller tumors. These gains have resulted in a current overall 5-year survival rate of 89% 
(www.cancer.org). The five-year relative survival by race is 90% for Caucasian women and 
3 
 
77% for African-American women (www.cancer.org). As with other cancers, detection at 
early stage is associated with better prognosis in breast cancer (Table 1.3). Paradoxically, 
improved screening technology (such as digital mammography) and its increasingly 
widespread use may partially account for the rise in breast cancer rates over the last 25 years, 
although the precise cause for the increasing incidence remains unknown. In the United 
States, breast cancer incidence rates increased sharply in the 1980s and continued to rise, 
although less rapidly, in the 1990s. Since 1999, incidence rates have declined by 
approximately 2% per year. In addition to the contribution of screening mammography to 
effective resulting in increased detection of breast cancers too small to be detected by 
palpation, the increase in incidence is also attributed to changes in reproductive patterns, like 
having fewer children and delayed age of childbearing, which are well known risk factors of 
breast cancer. Increase in breast cancer incidence in the late 1990s could also be related to 
increases in obesity and post-menopausal hormonal replacement therapy. The recent decline 
in breast cancer has been attributed to decreased utilization of hormone replacement therapy, 
as well as decrease in mammography prevalence [2-6]. 
 
Risk Factors for Breast Cancer 
 A number of etiological factors contribute to the risk of breast cancer. Established 
risk factors for breast cancer include (i) reproductive/hormonal factors like early menarche, 
late menopause, nulliparity, and late first full-term pregnancy, (ii) lifestyle factors like 
obesity and alcohol consumption, (iii) genetic factors like family history, mutations in 
BRCA1/2 genes, previous history of breast cancer, and (iv) high mammographic breast 
density [7-14]. Factors that may contribute to breast cancer risk include (a) 
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reproductive/hormonal factors like hormonal replacement therapy, and recent use of oral 
contraceptives, (b) lifestyle factors like smoking, diet, physical activity, breast feeding, and 
NSAID use, and (c) other factors like exposure to ionizing radiation. [14]. Although age and 
sex are considered the chief risk factors for breast cancer development, it is important to note 
that it is the combination of numerous factors that drives the initiation, development, and 
progression of breast cancers. Most of these risk factors increase the likelihood that a woman 
will develop breast cancer. However, having one or more of these risk factors does not confer 
100% chance that breast cancer will ever develop. 
 
Reproductive Factors 
Based on epidemiologic studies, a number of factors determining life-time exposure 
to estrogen have been established as risk factors for breast cancer. These factors are 
associated with reproductive history and include ages at menarche, parity, first birth, and 
menopause, as well as factors like infertility and nulliparity [7, 15]. The first recognition of 
the importance of life-time estrogen exposure included the observation of relatively higher 
incidence rates of breast cancer among nuns compared to the women who bore children [16]. 
The fact that more than two-thirds of breast cancers are stimulated by estrogen at some point 
during the course of cancer progression makes the association between estrogen exposure 
and breast cancer risk very important [7].  
 
Obesity 
Obesity is an independent risk factor for breast cancer development in post-
menopausal women [7, 14, 17, 18]. A pooled analysis showed an inverse relationship 
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between the baseline weight and body mass index (BMI) and breast cancer in pre-
menopausal women and a positive relationship in post-menopausal women [17]. The effects 
of weight gain during particular periods of lifetime on breast cancer risk have been 
investigated in numerous studies. Different studies have shown that weight gain during 
reproductive years increases the risk of postmenopausal breast cancer [19-21]. The effects of 
weight gain/excess weight during childhood on breast cancer risk are not very clear. A study 
by Berkey et al showed that higher childhood BMI was associated with reduced risk of pre-
menopausal breast cancer, but increasing BMI between 10 and 20 years of age did not reduce 
the risk of pre-menopausal or post-menopausal breast cancer [7, 22]. Other studies have 
shown a protective effect of excess weight in early years on risk of breast cancer [7, 23]. This 
protective effect was more pronounced and consistent in women who remained overweight in 
adult life ruling out the protective role of subsequent weight loss. The proposed mechanisms 
for this linkage include association of a longer period of anovulatory cycles after menarche in 
women with lasting obesity and the increased intake of substances that are ‘protective’ 
against the early events of breast carcinogenesis. Some studies found an independent 
association between the risk of breast cancer and presence of central adiposity, independent 
of BMI [24, 25]. However, other studies found no such association [26]. It has been 
suggested that adult obesity increases the risk of breast cancer by increasing the circulating 
levels of estrogen. Increased aromatase activity in adipose tissue and decrease in 
concentration of sex hormone binding globulin leads to an increase in the bioavailable 
estrogen, leading to increased breast cancer risk [7]. Obesity affects not only the risk factors 
for breast cancer, but also the disease prognosis through numerous pathways, including 
associated adverse disease features and morbidities that can hinder the treatment [17]. 
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Breast Density  
 Dense breast tissue seen on mammography and characterized by increase in stromal 
fibrosis and epithelial proliferation increases the risk for breast cancer [7]. After adjusting for 
known risk factors for breast cancer, case-control and cohort studies have shown an increased 
risk associated with high density mammographic parenchymal patterns compared with low 
density patterns [27-29]. The biological basis underlying this association is unclear. 
However, the attributable risk for breast cancer was estimated to be 30% for women with 
50% or greater breast density [27]. 
 
Diet and Physical Activity 
 In developed countries, factors in addition to reproductive factors and breast density 
may contribute to the high incidence of breast cancer. These include a high fat diet [30], low 
levels of physical activity, and obesity [31, 32]. Other factors like smoking [33] and alcohol 
consumption [34] may also play a role in determining the risk for breast cancer. High intake 
of fruits and vegetables has been linked to low incidence of cancer overall, but the 
association for decreasing the risk of breast cancer remains inconclusive [35].  Contradictory 
reports exist regarding the relationship between cigarette smoking and breast cancer [33, 36]. 
Studies that followed the immigration of Asian women (typically with low incidence of 
breast cancer) to Western countries provided evidence for the role of a Western diet in risk 
for breast cancer development. The first generation women of Asian-descent born in Western 
countries have breast cancer rates similar to those of Caucasians [37]. The Asian-American 
women born in the West have a 60% increase in breast cancer risk compared to Asian-
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Americans born in the East [37]. In another study, it was observed that Chinese women who 
ate a more traditional Eastern diet (high in vegetables) had half the risk of developing breast 
cancer compared to Chinese women who ate a more Westernized diet (high in meat, white 
bread, milk, etc.) [38].    
 
Genetic Factors 
 It is now well established that genetic factors play a strong role in the development of 
breast cancer. An affected first-degree relative (such as a mother, sister, or daughter) confers 
a two-fold to four-fold increased risk of developing breast cancer [7]. Genetic variations 
linked with increased breast cancer risk are classified as high-penetrance mutations, moderate 
penetrance variants, and low-penetrance polymorphisms [39]. High-penetrance mutations are 
associated with very high risk (relative risk with presence of these mutations – 5 to >20 fold) 
but are rare in the population, account for a relatively small percentage (about 20-25%) of the 
familial risk [39, 40]. The studies in 1990s discovering the association of BRCA1 and BRCA2 
with breast cancer significantly advanced the field of genetic susceptibility to breast cancer 
development. These linkage studies led to the seminal discovery that mutations in tumor 
suppressor genes, BRCA1 and BRCA2, confer a high risk of breast cancer. Breast cancer was 
linked to BRCA1 in 52% and to BRCA2 in 32% of the families with multiple cases of breast 
cancer. Likewise, in families with breast and ovarian cancers, linkage was established to 
BRCA1 in 84% and to BRCA2 in 14% of families [41, 42]. In addition to BRCA1 and/or 
BRCA2, other high-penetrance mutations have been identified, mostly as part of heritable 
cancer syndromes, including PTEN mutations in Cowden syndrome [43], TP53 mutations 
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found in Li-Fraumeni cancer syndrome [44, 45], and STK11/LKB1 mutations in Peutz-Jegher 
syndrome [46]. 
The moderate penetrance variants include the genes associated with moderate risk, 
and because of the relative low frequency of this class of genetic variants, their familial risk 
is estimated to be less than 3% [39]. These variants mainly affect the genes that are involved 
in DNA repair mechanisms including CHEK2 [47], PALB2 [48], BRIP1 [49], ATM [50], and 
MRE11 [51]. The low-penetrance polymorphisms are common and are associated with small 
increases in risk (relative risk <1.5 fold). It is believed that most otherwise unexplained 
familial risk maybe due to a polygenic mechanism involving multiple low-penetrance 
polymorphisms [39, 52]. Candidate gene studies and genome wide association studies have 
identified numerous breast cancer susceptibility loci. In some cases, these loci contain or are 
proximal to known genes like FGFR2, TOX3, MAP3K1, LSP1 [53] and RAD51L1 [54], in 
other cases these loci map to regions lacking gene density like 8q24 [53] and 2q35 [55, 56]. 
Using a statistical model, the low-penetrance polymorphisms detected so far are estimated to 
account for ~10% of familial risk, suggesting that many other variants remains to be detected 
[39]. 
 
Breast Cancer: A Heterogeneous Entity (Molecular Subtypes) 
  Breast cancer is not a single disease. Rather, breast cancer represents a diverse 
spectrum of diseases that includes several distinct biological entities and subtypes. These 
subtypes are associated with specific morphological characteristics and different clinical 
outcomes [57-65]. The molecular signatures of these breast cancer subtypes reflect not only 
the distinct biological features of these malignant neoplasms, but also predict their clinical 
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behavior and responses to chemotherapy [66-69], with certain subtypes having better 
outcomes than others. To some extent, the observed variation in disease outcome among 
breast cancer patients reflects the successful identification of therapeutic targets for some 
subtypes and the development of effective targeted therapies. The diverse spectrum of breast 
cancer includes a number of morphologic subtypes. Invasive ductal carcinoma is the most 
common morphological subtype, representing 80% of the invasive breast cancers. Invasive 
lobular carcinoma is the next most common subtype, representing approximately 10% of 
invasive breast cancers. The less common subtypes of the invasive breast cancers include 
mucinous, cribriform, micropapillary, papillary, tubular, medullary, metaplastic, and 
inflammatory carcinomas. Representative examples of invasive ductal carcinomas are shown 
in Figure 1.3. 
  Routine subclassification of invasive ductal carcinomas is accomplished by 
immunostaining tumor tissues for estrogen receptor (ER), progesterone receptor (PR), human 
epidermal growth receptors (HER1 and HER2), and various cytokeratins.  The differential 
expression of ER, PR, and HER2 in different subtypes of breast cancer based upon 
immunohistochemical staining is shown in Figure 1.3. The differential expression of these 
protein biomarkers is used as an immunohistochemical surrogate for gene expression 
analysis to determine molecular subtype.  Approximately 70-75% of invasive breast cancers 
express the estrogen receptor (ER+). Collectively, the ER+ malignant neoplasms are 
classified as luminal cancers. These cancers are further subclassified into luminal A and 
luminal B subtypes based on their HER2 status and proliferation rate.  The majority of ER+ 
tumors also express PR. The presence of normal PR levels suggests an intact ER signal 
transduction pathway in the breast cancer cells, and PR expression typically follows the ER 
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expression pattern. The ER- breast cancers are subclassified as HER2+ or basal-like based on 
the HER2 overexpression/gene amplification, basal cytokeratin expression, and EGFR 
(HER1) expression. An immunohistochemical staining proxy based on 5 biomarkers 
classifies breast cancers into the major subtypes (shown schematically in Figure 1.4): (i) 
Estrogen receptor positive cancers (ER+) are subclassified into luminal A (ER+,  PR+, 
HER2-) and luminal B (ER+, PR+, HER2+), (ii) Estrogen receptor-negative cancers (ER-) 
are subclassified into triple-negative breast cancer (ER-, PR-, HER2-), and human epidermal 
growth factor receptor 2-positive (ER-, PR-, HER2+), and (iii) unclassified cancers (negative 
for all 5 markers) [58-60, 70]. Basal-like breast cancers are distinguished from other triple-
negative breast cancers (ER-, PR-, HER2-) by expression of cytokeratin 5/6 and/or EGFR. 
There is no international consensus on the criteria used to define cancers as basal-like in 
formalin-fixed, paraffin-embedded tissues. Therefore, the term basal-like is not yet routinely 
used in clinical practice.  Rather, the basal-like breast cancers are contained in the triple-
negative classification. 
   Breast cancers, like most epithelial cancers, are associated with better treatment and 
survival outcomes when diagnosed at an early stage. However, outcomes of early stage 
breast cancers differ depending upon the molecular subtype (Figure 1.5). In general, with 
stage matched breast cancers, the ER+ breast cancer subtypes (luminal A and luminal B) 
exhibit a good prognosis and excellent long-term survival (approximately 80-85% 5-year 
survival), while the ER- subtypes (HER2-positive and basal-like) are difficult to treat and 
associated with poor prognosis (approximately 50-60% 5-year survival).  The ability of 
patients with ER+ breast cancers to survive their disease reflects the availability of effective 
targeted therapy in the form of anti-estrogen treatment (e.g., tamoxifen).  However, among 
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the ER+ breast cancers, the luminal B neoplasms are associated with a significantly worse 
prognosis than luminal A subtype [60] (Figure 1.5). This difference in outcome is partly due 
to variations in response of ER+ subtypes (luminal A and luminal B) to anti-estrogenic 
treatment [71]. Targeted therapy of HER2 overexpressing breast cancers, [luminal B or 
HER2-positive (ER-) neoplasms] with trastuzumab (Herceptin), either concurrent or 
sequential with adjuvant chemotherapy, has improved survival for these breast cancer 
subtypes [72].  
  Basal-like breast cancers are characterized by autonomy of growth that is independent 
of expression of hormone receptors. Since these cancers lack the appropriate targets for the 
drugs like tamoxifen (targeting ER) and trastuzumab (targeting HER2), patients with these 
cancers do not derive benefit from these drugs. Basal-like breast cancers are associated with 
overall poor prognosis and shorter long-term survival.  The poor clinical outcomes associated 
with basal-like breast cancer reflect the fact that these cancers are refractory to chemotherapy 
or recur following therapy. Lack of identification of ‘druggable’ targets in basal-like breast 
cancers and poor prognosis makes the identification of molecular signatures and therapeutic 
targets in these cancers to be of utmost significance. No widely available targeted therapies 
for this breast cancer subtype have been developed to date, although phase II studies of 
PARP inhibitors have shown promising results [73].   
 
    DNA Methylation Machinery Abnormalities in Breast Cancer   
  With the emergence of evidence demonstrating that genome modifications that do not 
alter DNA sequence make a substantial contribution to the regulation of gene expression, 
epigenetics has emerged as important mechanism contributing to the process of 
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carcinogenesis [74-76]. In contrast to genetic changes like deletions, translocations, and 
amplifications, epigenetic changes related to DNA methylation, genomic imprinting, and 
histone modifications are frequent, as well as reversible [77].  DNA methylation of CpG 
dinucleotides represents an epigenetic event of major importance in cancer induction and 
progression. A number of genes contain CpG-rich regions, known as CpG islands (defined as 
≥200 bp with ≥50% G+C content and ≥0.6 CpGs observed/CpGs expected) [78], in their 
promoter sequences proximal to the transcriptional start sites. CpG islands in regulatory 
regions of expressed genes are typically unmethylated, while transcriptionally silent genes 
are often associated with methylated CpG islands [76]. Alterations in methylation, both 
global hypomethylation and gene-specific hypermethylation are associated with neoplastic 
transformation [79-82]. Genome-wide demethylation may be associated with aberrant 
expression of some genes that could contribute to neoplastic transformation, tumorigenesis, 
or cancer progression [83, 84]. Also, demethylation can contribute to chromosomal 
instability by destabilizing pericentromeric regions of certain chromosomes [84-86]. 
Methylation-dependent gene silencing is a normal mechanism for regulation of gene 
expression [87]. However, in cancer cells methylation-dependent epigenetic gene silencing 
represents a mutation-independent mechanism of inactivation of tumor suppressor genes 
[88], genes associated with DNA repair or apoptosis. Recently, it was shown that genes 
lacking typical CpG islands are also susceptible to methylation-dependent silencing, 
indicating that methylation-dependent gene silencing is not limited to methylation events at 
cytosines within CpG islands [89]. This relationship between DNA methylation and gene 
silencing suggests that changes in normal methylation patterns can result in altered gene 
expression.  A significant number of genes that are involved in the hallmarks of cancer [90] 
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are subject to methylation-dependent silencing [91]. Epigenetic gene inactivation being at 
least as frequent, if not more so, than mutation in carcinogenesis [92-94], represents a 
fundamental aspect of cancer and plays a key role in neoplastic transformation and 
progression. 
   DNA methylation results from covalent addition of a methyl group from an S-
adenosyl-methionine donor to 5-position of cytosine in a CpG dinucleotide. This transfer is 
catalyzed by DNA methyltransferases with somewhat distinctive roles. To date, four human 
DNA methyltransferases have been identified: DNMT1, DNMT2, DNMT3a, and DNMT3b. 
However, DNMT2 was identified by sequence similarity alone and does not possess any 
recognized methyltransferase activity [95]. Functionally, two types of DNA 
methyltransferases are known to occur in vivo: (i) de novo methyltransferases that initially 
establish the methylation pattern of a given DNA segment, (ii) maintenance 
methyltransferases that ensure that the methylation patterns are faithfully copied to daughter 
strands. Typically, de novo methylation function is carried out by DNMT3a and DNMT3b, 
which are highly expressed during embryogenesis, but at lower levels in normal adult tissues 
[96]. Maintenance methylation is usually carried out by DNMT1 which is constitutively 
expressed in proliferating cells and has a significant preference for hemi-methylated 
substrates [97]. However, recent findings suggest that the roles of individual DNMTs are not 
clearly delineated and there is evidence of interplay and partial redundancy among these 
enzymes [97, 98]. For example, DNMT1 has been found to express de novo activity on 
unmethylated substrates which surpasses that of DNMT3a and DNMT3b [97]. Some studies 
suggest that DNMT3a and DNMT3b or DNMT1 and DNMT3b are jointly necessary for 
maintenance methylation of specific sequences [99-101].  
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  Numerous DNMT abnormalities have been associated with process of neoplastic 
transformation, carcinogenesis, and tumor progression.  Owing to the tissue-specific nature 
of findings related to DNMTs, many questions regarding the roles of individual DNMTs 
remain unanswered. Cancer cells, in general have higher methylation capabilities than 
normal cells, but the range of DNMT overexpression is quite wide, reflecting highly variable 
expression. The range of DNMT overexpression was shown to vary from 4-3000 fold in one 
study [102]. For example, in leiomyomas, DNMT3a and DNMT3b are decreased in 75% of 
the cases, in contrast to increased expression of DNMT1 in 50% of the cases [103]. Another 
study showed that ovarian cancer cell lines exhibit DNMT1 expression levels at three times 
normal, along with increased DNMT3b levels [104]. However, not all DNMTs are 
overexpressed in all cancer types. In another study comprised of colorectal, bladder, renal, 
and pancreatic cancers, a significant increase in the expression of DNMT3b was observed, 
but there was no overexpression of DNMT1 or DNMT3a [105]. This suggests that the type 
and extent of aberrant expression of different DNMTs in cancer cells is significantly 
determined by the tissue type. 
   Various studies based on the modulation of DNMT levels have been performed to 
dissect the roles of different DNMTs in the aberrant methylation seen frequently in different 
types of human cancer. Several studies found that inhibiting DNMT1 was sufficient to cause 
re-expression of methylation-silenced genes in bladder [106], lung [107], breast [107, 108], 
and colon [109] cancer cells. Other studies found that knocking down DNMT1 alone is not 
sufficient, and inhibiting DNMT3b in combination with DNMT1 is required for re-
expression of methylation-silenced tumor suppressor genes [110-112]. In a study in 
colorectal cancer cells, concomitant loss of both DNMT1 and DNMT3b, but not individual 
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loss, inhibited almost all methyltransferase activity [110], indicating that these enzymes act 
cooperatively. Additionally, DNMT3b was found to be overexpressed in a greater percentage 
of breast cancers than DNMT1 or DNMT3a, and was significantly related to more aggressive 
cancers and poorer prognosis in patients receiving adjuvant hormone therapy [113]. 
DNMT3b-overexpressing cancers demonstrated increased proliferation and were more likely 
to be ER-negative suggesting that overexpression of certain DNMTs may result in important 
differences in cancer biology. Overexpression of DNMT3b has been suggested to be 
involved in multistage carcinogenesis not only by affecting the expression of specific genes 
but also by inducing chromosomal instability [114]. The results of these studies largely 
depend on the cell type studied, method used to inhibit DNMT, methods used to detect 
methylation changes, and on the target genes examined for detecting methylation changes 
[115, 116]. 
   A number of different genes have been shown to be inactivated in breast cancer 
through methylation-dependent gene silencing, suggesting that epigenetic mechanisms play a 
major role in breast carcinogenesis [74]. These genes include but are not limited to cell cycle 
control genes (APC, RASSF1, RB, TFAP2A), tumor suppressor genes (CST6, BRCA1, 
PRDM2), metastasis-associated genes (CDH1, CEACAM6, LGALS3BP), steroid receptor 
genes (ESR1, PGR, RARα), and others [117-119].  For example, estrogen receptor (ESR1) is 
a steroid hormone receptor which activates transcription of cell growth genes. Loss of ESR1 
expression is associated with poor differentiation, insensitivity to hormonal therapy, and poor 
clinical outcome, and is an important prognostic factor in breast cancer [120]. A considerable 
percentage of breast cancers lack expression of the estrogen receptor (and other steroid 
receptors), but the loss of ESR1 expression is not always caused by deletion or mutation 
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[121]. Methylation-dependent silencing of the ESR1 gene is seen in as many as 46% of breast 
tumors [122, 123].  Adenomatous polyposis coli (APC) that exercises cell cycle control by 
regulating β-catenin-induced proliferation has been found to be methylated in 36-49% of 
primary breast tumors [124, 125] and the frequency of methylation seems to increase with 
tumor size and stage [126].  Therefore, APC methylation represents an independent marker 
of poor prognosis in breast cancer patients [127]. In addition, APC is often methylated 
concurrently with other biologically important genes such as RASSF1A [128]. Cystatin M 
(CST6) encodes a putative breast cancer suppressor gene and is silenced in many breast 
cancer cell lines and primary tumors through promoter hypermethylation [89, 129]. It has 
been shown that treatment with demethylating agents like 5-aza results in the re-expression 
of CST6 in breast cancer cell lines that normally lack expression of this gene [130]. E-
cadherin (CDH1) plays a vital role in the maintenance of cell-to-cell adhesion and 
suppression of metastasis [131]. The frequency of methylation for CDH1 is estimated to be 
between 53-72% for primary breast tumors and upto 90% for lymph node metastases making 
it one of the most commonly methylated genes in breast cancer [125, 132]. Methylation of 
CDH1 is an important marker for aggressive breast tumors as it is associated with a higher 
incidence of lymph node metastasis, poor differentiation, and decreased patient survival 
[133]. The vast number of genes reported to be silenced by methylation in breast cancer in 
association with the cellular activities in which they participate shows that methylation is 
likely to have a significant impact on clinical behavior in breast cancer.  
 
Hypermethylation Defect and Association with Basal-like Breast Cancer 
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  Some cancers exhibit aberrant concurrent hypermethylation of numerous genes, a 
phenomenon known as the CpG island methylator phenotype (CIMP). CIMP was first 
identified in colorectal carcinomas where it affects a distinct subset of tumors with high rates 
of concordant methylation of specific genes [134]. More recently, CIMP has been identified 
in other human cancers, including solid tumors like cancers of the ovary [135], bladder [136], 
prostate [136], lung [137, 138], stomach [139-142], liver [143], pancreas [144], esophagus 
[145], and kidney [146], neuroblastomas [147], as well as hematopoietic malignancies like 
leukemias and lymphomas [148, 149]. Despite the fact that many epigenetically-regulated 
genes are known to be directly silenced by DNA methylation in breast cancer, definitive 
evidence for a hypermethylation defect (similar to CIMP) among human breast cancers did 
not emerge until recently [150]. Previously, some investigators suggested that such a 
hypermethylation defect does not occur in breast cancer [151]. To characterize aberrant DNA 
methylation in human breast cancer, Roll et al examined the gene expression status of 64 
epigenetically-regulated genes in a panel of 16 breast cancer cell lines (BT-20, BT-549, 
HCC1937, HS578T, MCF-7, MDA-MB-231, MDA-MB-415, MDA-MB-435S, MDA-MB-
436, MDA-MB-453, MDA-MB-468, SK-BR-3, SUM102, SUM149, SUM185, and ZR-75-1) 
and the normal mammary epithelial cell line MCF12A. The genes were selected by including 
the genes aberrantly expressed in breast cancer and the genes known to be predictive of 
CIMP in other tumor systems. Unsupervised cluster analysis of gene expression patterns 
revealed two distinct groups of breast cancer cell lines that possess distinct methylation 
signatures: (i) hypermethylator cell lines, and (ii) non-hypermethylator cell lines [150]. The 
hypermethylator cell lines include BT-549, HCC1937, HS578T, MDA-MB-231, MDA-MB-
435S, MDA-MB-436, MDA-MB-453 SUM102, SUM149, and SUM185 and the non-
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hypermethylator cell lines include BT-20, MCF-7, MDA-MB-415, MDA-MB-468, SK-BR-
3, and ZR-75-1 [150]. The hypermethylation defect observed is associated with a 
characteristic gene expression signature that reflects methylation-dependent loss of 
expression of a panel of epigenetic biomarker genes (including CDH1, CEACAM6, CST6, 
ESR1, GNA11, MUC1, MYB, SCNN1A, and TFF3) [150].  Hypermethylator cell lines also 
exhibit higher total DNMT activity levels than that of non-hypermethylator cell lines and 
non-neoplastic MCF12A cells. Quantitation of the relative DNMT1, DNMT3a, and 
DNMT3b protein levels between hypermethylator and non-hypermethylator cell lines 
revealed that average DNMT1 and DNMT3a protein levels for the hypermethylator cell lines 
and the non-hypermethylator cell lines were indistinguishable from those of MCF12A.  In 
striking contrast to DNMT1 and DNMT3a, the average DNMT3b protein levels for the 
hypermethylator cell lines were much higher than those of the non-hypermethylator cell 
lines. In addition, a strong association between DNMT activity and DNMT3b protein levels 
was also observed. This hypermethylation defect that characterizes a subset of breast cancer 
cell lines reflects concurrent epigenetic silencing of methylation-sensitive genes secondary to 
overexpression of DNMT3b and DNA methyltransferase hyperactivity [150].   
  To determine if a similar hypermethylation defect could be detected in primary 
sporadic invasive breast cancers, microarray-based expression data from the UNC 
Microarray Database was examined.  An unsupervised cluster analysis of 90 tumors in one 
dataset from UNC revealed three major clusters. One of these clusters was composed of 21 
tumors (23%) that expressed a hypermethylation signature identified by low expression of 
seven or more genes out of the nine genes analyzed. Within this cluster, 100% (21/21) of the 
tumors were of the basal-like subtype and included 88% (21/24) of all basal-like tumors 
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within the dataset. The second cluster consisted of 51 tumors and was composed primarily of 
luminal A and luminal B breast cancers (65% and 29%), with one basal-like and two Her2+ 
cancers within this cluster. The third cluster consisted of 19 cancers with 84% (16/19) of 
these classified as Her2+ along with one luminal B and two basal-like cancers. These results 
suggest that expression of the hypermethylation defect may be associated with the basal-like 
subtype of breast cancer. In order to validate this suggestion, multiple datasets were 
analyzed, consisting of an expanded dataset from UNC containing 272 cancers (Figure 1.6), 
and datasets obtained from Hess et al [152] consisting of 133 primary breast cancers, Wang 
et al consisting of 295 primary breast cancers [153], and van de Vijver et al. composed of 
246 primary breast cancers [63]. The details of these analyses are summarized in Table 1.4 
and all these results were in concordance with the initial results from UNC dataset. In total, 
946 primary breast cancers were examined to explore the possibility that the hypermethylator 
signature is expressed by primary breast cancers in vivo. Among the tumors analyzed, 23% 
(220/946) exhibited the hypermethylation signature based on the rule (defined as having 
seven or more target genes with expression levels below the median). Among these 
hypermethylator cancers, 79% (174/220) were basal-like and out of all the basal-like cancers 
examined, 63% (174/277) were also hypermethylators. These findings suggest significant 
correspondence between expression of the hypermethylator defect and the basal-like subtype 
of breast cancers. 
 
 Basal-like Breast Cancer  
 Discovery of Basal–like Breast Cancers 
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  The basal breast cancer subtype was first described in studies based on 
immunohistochemistry [154-157]. These cancers are designated basal-like because they 
exhibit some cellular characteristics associated with the basal myoepithelial cell layer, such 
as expression of cytokeratins 5/6, 14, or 17, vimentin, and laminin, but these tumors are not 
derived only from myoepithelial cells [158-160].  The basal-like breast cancer subtype was 
rediscovered following the application of microarray-based gene expression profiling to 
breast cancer classification [57-61, 63, 64]. That the basal-like breast cancers were identified 
independently by two different methodologies indicates strongly that these cancers represent 
a distinct biological entity. Basal-like breast cancers are best classified through gene 
expression profiling [57-61, 63, 64]. However, in routine clinical practice, 
immunohistochemistry has become the surrogate for the gene expression analysis for 
diagnosis of basal-like breast cancers (Figure 1.3). Correctly classifying these cancers 
significantly impacts clinical decisions and research efforts. In the clinic, there is a need to 
correctly identify breast cancer subtypes for prognostication purposes in relation to 
individual patients and for decision-making related to appropriate treatment course. On the 
other hand, in the research environment, correct breast cancer subclassification is essential to 
ensure that investigations expand our understanding of the biological basis for the behavior 
and characteristics of these cancers. 
 
 Association with Risk Factors 
   The development of basal-like breast cancer is associated with distinct risk factors, 
including early-onset menarche, younger age at first full-term pregnancy, high parity 
combined with lack of breast feeding, and abdominal adiposity (based upon waist-hip ratio) 
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[161].  These breast cancers are over-represented among patients of certain age and ethnic 
groups, and are frequently associated with certain genetic mutations.  Specifically, basal-like 
breast cancer is over-represented among premenopausal African-American women [66].  
However, these cancers can and do affect women of every age and ethnic group [161].  The 
differences in distribution of basal-like breast cancer by age and race can be partially 
attributed to variations in the distribution of the risk factors described and to other risk 
factors (e.g., use of lactation suppressants and overexpression of leptin receptor) [161].  In 
addition, basal-like breast cancer occurs more frequently among hereditary breast cancer 
patients that harbor germ-line BRCA1 mutation [162]. Foulkes et al. showed that 17/72 
triple-negative breast cancers harbored a BRCA1 mutation and 88% (15/17) of these 
expressed the basal-like phenotype [163]. Likewise, Sorlie et al. observed that 100% (18/18) 
of breast cancers from patients carrying BRCA1 mutations clustered within the basal-like 
subgroup [60]. However, the other molecular subtypes of breast cancer can be associated 
with BRCA1 mutations as well.    
 
 Morphological Features 
  Morphologically, basal-like breast cancers are characterized by the presence of 
central necrotic zones, pushing borders, and conspicuous lymphocytic infiltrate [164-168]. 
The presence of metaplastic elements [59, 166-168] and medullary⁄atypical medullary 
features [167-169] are more prevalent in basal-like breast carcinomas than in other types of 
breast cancer.  Recent studies have shown that more than 90% of metaplastic breast 
carcinomas [59], as well as the majority of medullary carcinomas [169, 170], exhibit a basal-
like phenotype.  Basal-like breast cancers are aggressive, with the high rates of cellular 
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proliferation, high histological grade, and extremely poor clinical outcomes [59, 60]. These 
factors combine to account for the disproportionate contribution of basal-like breast cancer to 
breast cancer mortality. It has been suggested that the high level of cellular proliferation 
observed in these neoplasms might account for the over-representation of basal-like breast 
cancers among the so-called interval breast cancers (the cancers arising between annual 
mammograms). 
 
 Clinical Behavior of Basal-Like Breast Cancers 
  Currently, there is no consensus on the immunohistochemical criteria for the 
diagnostic classification of basal-like breast cancers.  Studies have shown that the profile 
constructed using ER-/PR-, HER2-, CK5/6+, and/or EGFR+  is 100% specific but only 55% 
to 76% sensitive [171]. Breast cancers that are ER-/PR-/HER2- are broadly classified as 
triple-negative neoplasms (Figure 1.3). The triple-negative breast cancers include most (or 
all) basal-like breast cancers [172]. Interpreting the percentage of positive cells and intensity 
of immunohistochemical staining is subjective. Variability in immunostaining techniques and 
procedures is a concern as well. Hence, standardization and/or automation of 
immunostaining procedures and interpretation to remove technical and subjective variation 
will benefit this analysis in the clinical laboratory.  The low sensitivity associated with 
classification of basal-like breast cancers using immunohistochemical staining may indicate 
that these cancers are much more heterogeneous than previously thought.  Gene expression 
profiling-based molecular classification of breast cancers predicts the general clinical 
behavior of breast cancers corresponding to the different molecular subtypes. Microarray 
studies show that the basal-like breast cancers express a common gene expression signature 
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and these cancers are associated with an extremely bad prognosis [59].  Among the patient 
cohort examined in the initial study of this type, 100% of the patients with basal-like subtype 
succumbed to their disease within four years of diagnosis [59].  Basal-like breast cancers 
respond to preoperative (neoadjuvant) chemotherapy [173, 174]. However, despite the 
observation of pathologic complete response in many patients, these individuals exhibit poor 
long-term survival. The poor survival outcomes among these patients despite response to 
chemotherapy may be related to a higher likelihood of relapse in individuals where 
pathologic complete response was not achieved [174]. 
   The malignant neoplasms that constitute the basal-like breast cancer subtype are not 
biologically homogeneous. For example, in one study, unsupervised hierarchical clustering 
within 43 cytokeratin-14 positive (basal-like phenotype) tumors revealed four clusters, and 
one of these displayed a worse prognosis than other three, strongly suggesting intra-subtype 
heterogeneity [175]. Variable prognosis within the basal-like subtype has also been reported 
by other groups [176, 177]. Rakha et al. divided the basal-like breast cancers into those with 
a “dominant basal pattern” (>50% of cells are positive for cytokeratin 5/6 and 14) and the 
remaining “basal” cancers (<50% of cells are positive for cytokeratin 5/6 and 14) [176].  
These subsets of basal-like breast cancers demonstrated differences in grade, presence of 
pushing margins, local spread, and long-term outcomes (disease-free survival and overall 
survival) [176].  Likewise, Laakso et al. distinguished “basal” (uniformly positive for 
cytokeratins 5 and 14) and “basoluminal” (heterogeneously positive for cytokeratin 
expression) subtypes of basal-like breast cancers, and showed that these subsets of basal-like 
cancers differ with respect to tumor size, proliferation index, expression of other markers 
(like vimentin), and recurrence-free survival [177].  These observations underscore the 
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necessity to further define biological subsets of basal-like breast cancer (particularly in terms 
of clinical behavior).  The pattern of metastatic spread among basal-like breast cancers has 
been suggested to be different compared to other breast cancer subtypes. The basal-like 
breast cancers have a tendency to disseminate through hematogenous routes, involving brain 
(resulting in higher rate of cerebral metastasis) and lung, and are less likely to spread to 
lymph nodes, liver, or bones [164, 178-180].  In general, cancer prognosis is linked to 
various clinical parameters, including tumor size, tumor grade, lymph node status, and the 
presence of distant metastasis.  However, among basal-like breast cancers, prognosis has 
been shown to be less dependent on tumor size, tumor grade, and lymph node status 
reflecting the deviant nature of these cancers. Expression of basal markers like cytokeratins 
5/6 was associated with poor outcome and proved to be a prognostic factor independent of 
the usual clinical parameters  [181].  These observations highlight the requirement to 
examine further the transcriptome of basal-like breast cancers in order to uncover the 
molecular basis for the biological behavior of subsets of these cancers [181]. 
 
  Prognosis 
   Neoplasms representing different subsets of basal-like breast cancers may have the 
same clinical stage based on traditional classification criteria and may be histologically and 
morphologically similar, yet their biological (clinical) behavior may be remarkably different.  
Survival rates associated with basal-like breast cancers are dismal. Numerous studies have 
shown that patients with basal-like breast cancer exhibit significantly shorter overall survival 
(OS) and disease-free survival (DFS), and have high rates of tumor recurrence, highlighting 
the aggressive course of these cancers. A retrospective study of 49 basal-like and 49 grade 
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and age-matched non basal-like tumors [182] showed that patients with basal-like breast 
cancers were associated with significantly shorter disease-free and overall survival, and a 
higher recurrence rate. Another study based upon a cohort of 930 breast cancer patients 
showed that expression of basal cytokeratins (indicative of basal-like phenotype) was 
associated with poor progression-free survival and poor overall survival [171]. Analysis of 
496 primary breast cancers from the Carolina Breast Cancer Study showed that progression-
free survival differed by breast cancer subtype and survival time is significantly shortened in 
basal-like and HER2+ subtypes [66]. These studies are consistent with similar observations 
of poor prognosis in basal-like cancers made by numerous other groups before and after these 
aforementioned studies [59-61, 69, 181, 183, 184].  In the absence of molecular targets (like 
ER or HER2), options for basal-like breast cancer therapy are limited to aggressive cytotoxic 
chemotherapy. However, cytotoxic chemotherapy (whether neoadjuvant or adjuvant) has 
proven largely ineffective in the treatment of basal-like breast cancer based on OS among 
these patients. The general failure of chemotherapy in the treatment of basal-like breast 
cancer may be related to the lack of targeted approaches and/or our current inability to 
stratify patients according to their likelihood of response to specific drugs or treatment 
modalities. 
 
Post-transcriptional Regulation of DNMT3b by MicroRNAs 
DNMT3b is constitutively expressed by all mammalian cell types, but is often 
overexpressed in cancer [105, 113, 185, 186]. However, unlike other genes that are 
overexpressed in cancer, the mechanisms accounting for increased DNMT3b levels 
infrequently involves gene mutation and/or gene amplification [187]. Likewise, increased 
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DNMT3b transcription due to increased trans-activation does not commonly occur in cancer 
[187]. Rather, it is now recognized that DNMT3b is subject to post-transcriptional regulation 
by microRNAs (miRs), which are small endogenous non-coding RNAs (19-25 nucleotide 
long) that have emerged as key players in regulation of gene expression [188]. miRs were 
discovered approximately 20 years ago when investigators determined that the traditionally 
non-functional areas of the genome had gene regulatory capabilities and were later termed 
microRNAs [189-191]. The post-transcriptional regulation by miRs occurs through 
sequence-specific targeting of mRNAs as a result of recognition of complementary sites, 
most often in the 3’ untranslated region (UTR) of the target mRNA, producing either 
translational repression or degradation of the target mRNA [189, 192-195]. Less frequently, 
miRs have also been documented to target 5’UTRs and coding regions of mRNAs [196-198]. 
Recently, it has been shown that miRs can also target proteins where a novel function of 
miRs called ‘decoy activity’ was reported. It was shown that miR-328 regulates RNA-
binding protein by interacting with a ribonucleoprotein, hnRNP-E2 [199]. miRs are 
expressed in a tissue-specific manner and have been implicated in the regulation of several 
biological processes, including cellular proliferation, differentiation, apoptosis, and 
development [200-203]. More than 30% of the human transcriptome is estimated to be 
targeted by microRNAs [191]. A single miR can target multiple mRNAs and a single mRNA 
can be targeted by multiple miRs. A single miR or a group of miRs can therefore regulate 
pathways that are essential to biological/pathological processes like angiogenesis, survival 
and growth that can directly affect cancer cell behavior. Some miRs also participate in or 
trigger feedback or feedforward loops by cooperating with their target genes, further 
complicating the network of gene-regulation [204, 205]. More than 1000 miRs have been 
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identified in human genome, although it is predicted that many more may exist that are yet 
unidentified [206]. 
miR biogenesis is a complex system that involves multiple steps and several 
enzymes. Within the nucleus, a long transcript known as pri-miRNA is first transcribed by 
RNA polymerase II [188, 207]. Pri-miRNA is cleaved by RNAse III endonuclease Drosha to 
a smaller hair pin, precursor miRNA (pre-miRNA) approximately 70 nucleotides long [208, 
209]. RNAse Drosha belongs to a family of double stranded RNA specific ribonucleases and 
acts in combination with its partner, DGCR8, forming the processing complex called the 
Microprocessor [210, 211]. The pre-miRNA is transported out of the nucleus into the 
cytoplasm by the nuclear export protein, Exportin 5 [212]. Pre-miRNA in the cytoplasm is 
subsequently cleaved by another RNAse III enzyme Dicer that acts in conjunction with 
RNA-binding protein, TRBP, to yield double stranded miR molecule approximately 22 
nucleotides in length [191, 213]. This double stranded molecule consists of mature 
miRNA/miRNA nucleotide duplex that is separated into two single-stranded molecules; the 
mature miR gets incorporated into the RNA-induced Silencing Complex (RISC) and the 
other strand undergoes degradation [188, 214]. The ‘seed’ region comprised of nucleotides 2-
7 of the mature miR sequence specifies the target mRNA that the miR will bind to and is 
critical in determining the effect in terms of degradation of mRNA or inhibition of translation 
[188, 191].  
 More than half of human miR genes have been identified in fragile sites and are 
hence susceptible to alterations like deletion, translocation and amplification. Dysregulation 
of miRs has been shown to play oncogenic as well as tumor suppressor roles depending on 
the disease/pathway involved and the tissue affected [191].  Altered miR expression is 
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associated with several types of human cancer, including breast cancer [215-218]. The 
deregulated pattern of expression of miRs between normal and cancerous tissues in breast 
cancer has been extensively studied. The expression patterns of different miRs have been 
correlated with tumor stage, estrogen and progesterone receptor expression, proliferation 
index, vascular invasion, epithelial to mesenchymal transition, metastasis and 
neovascularization [216, 219-221].  miR-155, miR-21, miR-17-922, miR-182, miR-200, and 
miR-9 have been shown to be overexpressed in multiple studies in breast cancer; likewise let-
7, miR-143/145, miR-10b, miR-125b, and miR-126 have been shown to be downregulated 
[188, 191, 205, 214, 216, 219, 222]. Circulating miRs are also being explored as noninvasive 
biomarkers for the purposes of diagnosis as well as surveillance of disease status in breast 
cancer as well as other malignancies.   
Recent studies have identified miRs as both regulators of DNA methyltransferase 
(DNMT) expression and targets of aberrant DNA methylation in various tissue types. The 
miR-29 family (miR-29a, miR-29b, and miR-29c) directly targets DNMT3a and DNMT3b in 
lung cancer [223] and acute myeloid leukemia [224]. Likewise, the miR-148 family (miR-
148a and miR-148b) regulates DNMT3b in cell lines of multiple origin, including the MCF-7 
breast cancer cell line [225]. There is evidence that miRs not only regulate epigenetic 
machinery but are also epigenetically regulated themselves. In human bladder cancer, miR-
127 is silenced by promoter hypermethylation [226]. In similar fashion, miR-148a is 
epigenetically silenced in human cancer cell lines established from lymph node metastasis 
from colon, melanoma, and head and neck, suggesting that epigenetic loss of miR-148 is 
associated with progressive changes such as development of metastatic potential [217]. All of 
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these observations indicate direct interactions as well as cross-talk between the DNA 
methylation machinery and miRs. 
 
Objective of This Dissertation Research  
The objective of this project was to understand and characterize the contribution of 
DNMT3b to the biology and clinical outcome of basal-like breast cancers and to elucidate the 
role of microRNAs in dysregulation of DNMT3b expression among these breast cancers. To 
address our objective, we employed an experimental model of human basal-like breast cancer 
that is based on (i) well characterized hypermethylator cell lines that exhibit DNMT3b 
hyperactivity, and (ii) primary human breast cancers of known molecular classification. In 
this study, we analyzed the combination of epigenetic treatment and chemotherapy in three 
hypermethylator breast cancer cell lines. The purpose was to evaluate the effectiveness of 
targeting the DNA methylation machinery to modify the sensitivity of breast cancer cells to 
cytotoxic drugs. Epigenetic treatment was accomplished through (i) pharmacologic inhibition 
of DNA methyltransferase activity using 5-aza-2’-deoxycytidine (5-aza), and (ii) targeted 
inhibition of overexpressed DNMT3b using RNAi-mediated DNMT3b knockdown (KD). 
The results show that 5-aza pretreatment sensitizes hypermethylator breast cancer cells to cell 
killing by cytotoxic drugs, and that the improved chemotherapeutic efficacy is a function of 
dose and duration of exposure to 5-aza. We also observed an increase in the effectiveness of 
chemotherapeutic drugs after targeted inhibition of DNMT3b. These results demonstrate that 
DNMT3b is an excellent target for development of rational therapeutic approaches for 
hypermethylator breast cancers (such as basal-like breast cancers). We provide proof-of-
concept that targeting DNMT3b in hypermethylator breast cancer cells sensitizes them to cell 
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killing by cytotoxic drugs and that this strategy can be exploited to improve the efficacy of 
breast cancer chemotherapy.  
We analyzed breast cancer cell lines for differential expression of regulatory miRs to 
determine if loss of miR-mediated post-transcriptional regulation of DNMT3b represents the 
molecular mechanism that governs the overexpression of DNMT3b that drives the 
hypermethylation defect in breast cancer. The results show that multiple miRs (miR-29c, 
miR-148a, miR-148b, miR-26a, miR-26b, and miR-203) post-transcriptionally regulate 
DNMT3b in combination and loss of expression of these regulatory miRs contributes to 
DNMT3b overexpression in hypermethylator cell lines. We observed that enforced 
expression of regulatory miRs results in reduced DNMT3b mRNA levels in hypermethylator 
breast cancer cell lines, and that down-regulation of regulatory miRs results in increased 
DNMT3b mRNA levels in non-hypermethylator breast cancer cell lines. These observations 
combine to suggest that the loss of multiple regulatory miRs that post-transcriptionally 
regulate DNMT3b levels represents the molecular mechanism governing the DNMT3b-
mediated hypermethylation defect in breast cancer cell lines. In addition, we examined the 
expression of microRNAs (miRs) that regulate DNMT3b in primary breast cancers and 
normal mammoplasty tissues to determine the mechanism governing DNMT3b 
overexpression in the hypermethylation defect. Examination of methylation-sensitive gene 
expression in primary breast cancers showed that majority of basal-like tumors express the 
hypermethylation defect as compared to other molecular subtypes of breast cancer. 
Significantly reduced expression of miR-29c distinguished basal-like cancers from other 
subtypes. miR expression patterns revealed two groups among the basal-like breast cancers 
corresponding to diminished expression and normal levels of expression. Our results suggest 
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strongly that (i) reduced expression of miR-29c is characteristic of basal-like breast cancers, 
(ii) two subgroups of basal-like breast cancers can be identified based on miR expression and 
methylation-sensitive gene expression, and (iii) the subgroup of basal-like breast cancers 
with reduced expression of multiple regulatory miRs express the hypermethylation defect. 
We provide proof-of-concept that targeting DNMT3b in hypermethylator breast cancer cells 
sensitizes them to cell killing by cytotoxic drugs and that this strategy can be exploited to 
improve the efficacy of breast cancer chemotherapy. Our results strongly support the 
suggestion that loss of miR expression may account for the DNMT3b-mediated 
hypermethylation defect among basal-like breast cancers and this significant molecular 
alteration present during the process of breast carcinogenesis can be targeted to significantly 
alter the prognosis of breast cancer. 
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Table 1.1. Breast Cancer Incidence for American Women, By Ethnicity (Age-Adjusted 
Incidence Rate From 2004-2008). These data were adapted from the SEER Cancer Statistics 
Review (www.seer.cancer.gov). 
Race/Ethnicity 
Incidence 
(per 100,000 women) 
All Ethnicities 124.0 
Caucasian/White 127.3 
African-American 119.9 
Asian/Pacific Islander 93.7 
American Indian/Alaskan Native 77.9 
Hispanic 78.1 
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Table 1.2.  Breast Cancer Mortality for American Women, By Ethnicity (Age-Adjusted 
Mortality Rate From 2003-2007). These data were adapted from the SEER Cancer Statistics 
Review (www.seer.cancer.gov). 
 
Race/Ethnicity 
Mortality 
(per 100,000 women) 
All Ethnicities 24.0 
Caucasian/White 23.4 
African-American 32.4 
Asian/Pacific Islander 12.2 
American Indian/Alaskan Native 17.6 
Hispanic 15.3 
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Table 1.3. Stage Distribution and 5-year Relative Survival By Stage at Diagnosis for  
Females, All Races, 2001-2007. These data were adapted from the SEER Cancer Statistics 
Review (www.seer.cancer.gov). 
 
Stage at Diagnosis 
Stage  
Distribution 
(%) 
5-year  
Relative Survival 
(%) 
Localized  
(confined to primary site) 60 98.6 
Regional 
 (spread to regional lymph nodes) 33 83.8 
Distant 
 (cancer has metastasized) 5 23.4 
Unknown 
 (unstaged) 2 52.4 
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 Table 1.4. Association of Hypermethylation Defect with Basal-like Breast Cancer.  
 
Dataset 
Number 
of 
Cancers 
Hypermethylator 
Cancers (%) 
Molecular Subtypes 
Among 
Hypermethylator 
Cancers 
% of Basal-like 
that are 
Hypermethylator
Expanded 
UNC1 272 
80/272  
(29%) 
65/80 (81%) Basal 
1/80 (1%) LB 
1/80 (1%) HER2+ 
13/80 (16%) CL 
65/103  
(63%) 
Hess et al. 
[152] 133 
33/133  
(25%) 
26/33 (79%) Basal 
4/33 (12%) HER2+ 
2/33 (6%) LA/B 
1/33 (3%) NL 
26/32 
 (81%) 
Wang et al. 
[153] 295 
59/295  
(20%) 
44/59 (75%) Basal 
12/59 (20%) LA/B 
3/59 (5%) HER2+ 
44/76  
(58%) 
Van de 
Vijver et al. 
[63] 
246 
48/246  
(20%) 
39/48 (81%) Basal 
7/48 (15%) LA/B 
2/48 (4%) HER2+ 
39/66  
(59%) 
Total 946 
220/946  
(23%) 
174/220(79%) Basal 
22/220 (10%) LA/B 
6/220 (3%) HER2+ 
14/220 (6%) other 
174/277  
(63%) 
 
Subtypes abbreviated as follows: luminal A (LA), luminal B (LB), claudin-low (CL), 
normal-like (NL), HER2 overexpressing (HER2+), and Basal-like (Basal) 
1 https://genome.unc.edu/   
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Figure 1.1 Age-Specific SEER Incidence Rates by Cancer Site All Ages, All Races Female; 
1992-2008. The graph showing incidence rate per 100,000 women at different age intervals 
below 1 year to 85+ years of age from 1992-2008. These observations were made based on 
SEER Cancer Statistics Review (www.seer.cancer.gov). 
  
  
 
  
  
38 
 
39 
 
Figure 1.2. Age-Specific SEER Incidence Rates by Race and Sex (Female), All Ages, 1992-
2008. The graph shows age-specific incidence rate per 100,000 women of different races 
from 1992-2008. These data were adopted from the SEER Cancer Statistics Review 
(www.seer.cancer.gov). The red line indicates the incidence in Caucasian females, the blue 
line indicates the incidence in African-American females, the green line indicates the 
incidence in Asian/Pacific Islander females, the purple line indicates the incidence in 
American Indian/AK Native females, and the yellow line indicates the incidence in Hispanic 
females. 
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Figure 1.3. Differential Expression of Estrogen Receptor (ER), Progesterone Receptor (PR), 
and Human Epidermal Growth Receptor 2, (HER2) Among Different Subtypes of Breast 
Cancer. Breast cancer is classified into various subtypes based on differential 
immunohistochemical staining for ER (Panels B, F, J, and N show immunostaining for ER 
and the results, ER+ or ER-, are indicated), PR (Panels C, G, K, and O show immunostaining 
for PR and the results, PR+ or PR-, are indicated), HER2 (Panels D, H, L, and P show 
immunostaining for HER2 and the results, HER2+ indicative of HER2 amplification or 
HER2-, are indicated), HER1 (not shown), and cytokeratins (not shown). Panels A-D, 
luminal A breast cancer; Panels E-H, luminal B breast cancer; Panels I-L, HER2+ breast 
cancer; Panels M-P, basal-like breast cancer. Panels A, E, I, and M show H&E staining for 
each breast cancer subtype.  
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Figure 1.4.  Molecular Subtypes of Breast Cancer. The blue and pink rectangles group the 
subtypes based on the expression of ER/PR, positive in the blue (Luminal A and Luminal B) 
and negative (HER2+ and Basal-like) in the pink. The central grey rectangle (with black 
outline) indicates the presence of HER2 amplification in Luminal B and HER2+ subtypes. 
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Figure 1.5. Survival Plot of 294 Breast Cancer Patients. A Kaplan-Meier survival plot of 
overall survival corresponding to 294 breast cancers from the publicly available UNC 
database is shown grouped by molecular subtype. The plot was generated by Dr. Joel S. 
Parker (UNC Lineberger Cancer Center, UNC Chapel Hill). The p-value was calculated 
using the Log-rank test. Details of these 294 samples along with clinical annotation can be 
found at https://genome.unc.edu/pubsup/breastGEO/.  
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Figure 1.6. Microarray Analysis of 272 Primary Breast Tumors from Expanded UNC 
Database Suggests a Linkage Between Basal Breast Tumors and the Hypermethylator 
Phenotype. Supervised analysis of microarray expression data from the Expanded UNC 
microarray database. Gene expression patterns for individual tumors were analyzed to 
determine the expression of hypermethylation defect. Cancers with ≥7 genes below the 
median expression level were classified as hypermethylators. Microarray data mining 
analysis was performed by Dr. Wendell Jones (Expression Analysis, Durham, NC). Red 
indicates high level expression, green indicates low level expression, and black indicates 
normal expression levels for the genes of interest. The hypermethylator cluster is highlighted 
with a red rectangle. This cluster demonstrates concurrent downregulation of genes indicative 
of the hypermethylation defect and is predominately (81%) composed of basal-like cancers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
 
 
Methods Related to Chemotherapy Experiments 
Hypermethylator Breast Cancer Cell Lines and Cell Culture Conditions 
 Human breast cancer cell lines BT549 (ATCC# HTB122), Hs578T (HTN126), and 
MDA-MB-453 (HTB131) were obtained from the Tissue Culture Core Facility of the UNC 
Lineberger Comprehensive Cancer Center (Chapel Hill, NC). These cell lines exhibit high 
levels of total DNA methyltransferase (DNMT) activity, overexpression of DNMT3b, and 
concurrent silencing of multiple methylation-sensitive genes (including CEACAM6, CST6, 
ESR1 and SCNN1A) [150].  Breast cancer cell lines were grown in medium recommended by 
the ATCC (http://www.atcc.org/). Hs578T and MDA-MB-453 cells (and derivative cell 
lines) were cultured in Dulbecco’s modified Eagle’s medium, supplemented with 4 mM L-
glutamine, 10 μg/ml insulin (Gibco/Invitrogen Life Technologies Grand Island NY), 10% 
fetal bovine serum (Hyclone, Logan, UT), and 1% Antibiotic-Antimycotic (Gibco/Invitrogen 
Life Technologies). BT549 cells (and derivative cell lines) were cultured in RPMI-1640 
medium (Gibco/Invitrogen Life Technologies) containing 10% fetal bovine serum (Hyclone), 
and 1% Antibiotic-Antimycotic (Gibco/Invitrogen Life Technologies). Growth medium was 
refreshed three times weekly unless otherwise specified for demethylating and/or cytotoxicity 
assays. Cells were maintained at 37ºC and 5% CO2. 
 
Generation of DNMT3b KD and Scrambled Control Cell Lines 
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  Expression vectors for DNMT3b shRNA and scrambled control were used to target 
the overexpressed DNMT3b protein associated with the hypermethylation defect in human 
breast cancer cell lines [150]. These expression vectors were a kind gift from the laboratory 
of Dr. P.P. Jagodzinski (Poznan University of Medical Sciences, Poznan, Poland) and their 
construction has been described [227]. Briefly, the expression vectors were constructed in 
pLVTHM transfer plasmids with a DNMT3b-specific oligonucleotide (5’-CGC GTC CCC 
AGA TGA CGG ATG CCT AGA Att caa gag aCT CTA GGC ATC CGT CAT CTT TTT 
TGG AAA T-3’) or a scrambled control oligonucleotide (5’-GAT CCC GGA CAA GGG 
TCC TGA TCG TTt tca aga gaA ACG ATC AGG ACC CTT GTC CTT TTT TGG-3’) 
[227]. The resulting pLVTHMDNMT3b and pLVTHMSCRAM vectors express the targeting or 
control oligonucleotides from the H1 promoter, and each vector contains the green 
fluorescence protein (GFP) gene enabling the monitoring of transfection efficiency and 
plasmid retention in transfected cells. Breast cancer cells were grown in a six-well 
polystyrene plate to 60-70% confluency in 2.5 ml of complete growth medium for 
pLVTHMDNMT3b and pLVTHMSCRAM transfection with 2.5µg plasmid DNA using TransIT-
LT1 Transfection reagent (Mirus, Madison, WI) according to manufacturer’s protocol. After 
48 hours the presence of GFP+ cells was assessed in the knockdown and scrambled control 
transfected cells. Selection of positively transfected cells was accomplished using expression 
of GFP as a selectable marker. Transfected cell lines (DNMT3b KD and scrambled control) 
were subjected to flow sorting under sterile conditions at the UNC Flow Cytometry Core 
Facility (Chapel Hill, NC) to select for pure populations of GFP+ cells. Post-sort analysis of 
isolated cell populations indicated that 95-98% of cells were strongly GFP+. GFP expression 
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in the post-sort populations was monitored weekly by fluorescence microscopy to ensure the 
continual presence of the transfected plasmids. 
 
Demethylating Treatment of Breast Cancer Cell Lines with 5-Aza-2’-Deoxycytidine  
 5-aza-2’-deoxycytidine (5-aza, Cat # A3656, Sigma-Aldrich, St Louis, MO) was 
employed as a demethylating agent. Stock solutions of 5-aza (5 mM) were prepared in 
dimethyl sulfoxide (Cat # D2650, Sigma Chemical Company).  Founder populations of 
breast cancer cells were propagated in freshly made growth medium (described above) 
containing 250 nM, or 500 nM 5-aza for 3 days or 7 days, with re-feeding of fresh medium 
containing the drug each day. Re-feeding of cultures every day eliminates concerns about the 
half-life of 5-aza in culture medium, and insures a constant exposure to the drug.  Control 
populations of cells (no drug exposure) were maintained in parallel to treated cultures. Low 
concentrations of 5-aza (≤500nM) were used to avoid cytotoxicity, which can be observed at 
higher doses [89]. No evidence of 5-aza-related cytotoxicity was noted in this study. At the 
conclusion of the demethylating pretreatment, cells were trypsinized, counted, and plated in 
24-well plates at a concentration of 50,000 cells per well for subsequent exposure to 
cytotoxic drugs. 
 
Chemotherapeutic Drugs  
 Chemosensitivity assays were carried out using three chemotherapeutic drugs: 
Doxorubicin (Adriamycin; CAS 23214-92-8), Paclitaxel (Taxol; CAS 33069-62-4), and 5-
Fluorouracil (Adrucil; CAS 51-21-8). The drugs were obtained from Sigma-Aldrich 
(Doxorubicin, Cat # 44583; Paclitaxel, Cat # T7191; 5-Fluorouracil, Cat # F6627). The stock 
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solution of Doxorubicin (DOX; 20 µM) was prepared in sterile water, and stock solutions of 
Paclitaxel (PAX; 11.71 mM) and 5-Fluorouracil (5-FU; 100 mM) were made in dimethyl 
sulfoxide.  Stock solutions were stored as recommended by the manufacturer.  
 
Cytotoxicity Assays  
 MDA-MB-453, BT549, and Hs578T cells, their derivative cell lines (transfected with 
pLVTHMDNMT3b or pLVTHMSCRAM) and cells after demethylating treatment were analyzed 
for sensitivity to DOX, PAX, and 5-FU. Cells were trypsinized, counted, and plated in 24-
well plates at a concentration of 50,000 cells per well. After 24 hours, cells were exposed to 
fresh medium containing a range of doses of chemotherapeutic drugs for 72 hours (DOX, 0-1 
µM; PAX, 0-5 nM; 5-FU, 0-6 mM). At the end of the treatment period, the MTT assay was 
used to quantitate residual viable cells. The stock solution (5 mg/ml) of MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] (Cat # M5655, Sigma-Aldrich) was 
made in Dulbecco’s Phosphate Buffered Saline (Cat # 14190, Gibco/Invitrogen Life 
Technologies). The drug containing medium was replaced with a 10% solution of MTT in 
complete growth medium and cells were incubated at 37º C with 5% CO2 for four hours. The 
resulting pigment was solubilized with 0.1 N HCl in isopropanol and absorbance readings 
were taken at 570 nm (minus background absorbance at 690 nm). All the assays were 
performed in triplicate. The result of each treatment was expressed as a percentage of viable 
cells remaining relative to untreated control cells.  
 
Determination of Chemotherapeutic Drug Efficacy 
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 The half maximal inhibitory concentration (IC50) for each drug was estimated using 
GraphPad Prism Version 5.00 (GraphPad Software, San Diego, CA) [228].  Data points were 
fitted to sigmoidal dose-response curve with variable slope using Y= 100/[1+10^{(LogIC50-
X)*HillSlope)}]  where X is the logarithm of concentration and Y is the response (GraphPad 
Prism Version 5.00). All IC50 values expressed in this study reflect 72 hrs of drug treatment. 
 
DNMT3b Protein Analysis by Western Blotting  
 Cultured cells (corresponding to MDA-MB-453, Hs578T or BT549 breast cancer 
cells) and their derivative cell lines (transfected with pLVTHMDNMT3b or pLVTHMSCRAM) 
were lysed in 1x phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 8 mM 
Na2PO4, 2 mM KH2PO4, pH 7.4) containing 0.1 mM phenylmethanesulphonylfluoride 
(PMSF), 1 µg/ml pepstain A, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 1 mM β-glycerol 
phosphate, 1 mM sodium orthovanadate, and 0.1% Triton X-100. Cell lysates were utilized 
for western analysis using standard methods. Protein concentrations were determined using 
the Bradford assay (BIO-RAD Quick Start Bradford, Cat. # 500-0205). Protein lysates (20 – 
40 µg) were resolved on 8% SDS-PAGE gels, followed by transfer onto polyvinylidene 
difluoride (PVDF) membranes (Cat. #162-0184, BIO-RAD Sequi-Blot PVDF, 0.2 µM pore 
size, Millipore; Billerica, MA).  PVDF membranes were blocked for 30 minutes in TBST (10 
mM Tris-Cl, pH 7.6, 150 nM NaCl, 1% Tween-20) containing 5% milk, and then incubated 
with either anti-DNMT3b mouse monoclonal antibody (Cat # IMG-184A Imgenex, San 
Diego, CA) diluted 1:5000 or anti-actin rabbit polyclonal antibody diluted 1:10,000 (Cat # 
sc-1616 Santa Cruz Biotechnology, Santa Cruz, CA) overnight in TBST containing 1% milk.  
Subsequently, membranes were washed with TBST 3 times for 5 minutes, and then incubated 
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with a sheep anti-mouse (1:5000, Cat # NA931 GE Healthcare; Piscataway, NJ) or donkey 
anti-rabbit (1:10,000, Cat # NA934 GE Healthcare; Piscataway, NJ) horseradish peroxidase-
conjugated secondary antibody in TBST containing 1% milk for 1 hour at room temperature.  
The membranes were washed with TBST 3 times for 10 minutes each, and bound primary 
antibody was detected using ECL-Plus substrate (GE Healthcare; Piscataway, NJ).Western 
blots were quantitated using the image analysis tools contained in Adobe Photoshop 6.0. The 
absolute intensity of individual protein bands was calculated from measures of total pixel 
count and mean pixel density. Levels of DNMT3b protein were expressed relative to actin. 
 
Expression Analysis of Methylation-Sensitive Genes 
  RNA was prepared from breast cancer cell lines, their transfected derivative cell lines 
(carrying pLVTHMDNMT3b or pLVTHMSCRAM), and cells following demethylating treatment 
(7 days treatment with 250 nM or 500 nM 5-aza).  Total RNA was isolated utilizing the 
method of Chomczynski  and  Sacchi [229], modified  to  utilize  TRIzol  Reagent  
(Invitrogen  Life  Technologies,  Carlsbad,  CA), according  to  the  manufacturer's  protocol. 
Nucleic acid samples were DNAse (Cat # M610A; Promega, Madison, WI) treated (0.02 
U/µl at 37ºC for 30 minutes), and purified using the Qiagen RNeasy mini-kit (Cat # 74104; 
Qiagen, Valencia, CA). Isolated RNA was quantified after extraction using a Nanodrop 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
 Gene expression analysis was accomplished by real-time PCR utilizing an ABI 7500 
Real Time PCR System (Applied Biosystems, Foster City, CA). Total RNA samples (2 μg) 
were reversed transcribed using the High Capacity cDNA Reverse Transcription Kit (Part # 
4368814 Applied Biosystems) according to the manufacturer's protocol. Real-time primers 
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and probes for CEACAM6 (Hs00366002_m1), CST6 (Hs00154599_m1), ESR1 
(Hs00174860_m1), SCNN1A (Hs00168906_m1), and β-actin (Hs99999903_m1) were 
purchased from Applied Biosystems.  All real-time PCR reactions were performed in 
triplicate using TaqMan Universal PCR Master Mix (Cat # 4324018, Applied Biosystems) in 
20 µl volume (10 µl Taqman Universal PCR Master Mix, 1.0 µl TaqMan Real-time primers 
and probes, and 9 µl cDNA and nuclease-free water) and the following amplification 
conditions: 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. 
Gene expression levels were normalized using β-actin for each cell line and differences in 
gene expression were determined using the comparative Ct method described in the ABI 
Prism 7700 User Bulletin #2 (Applied Biosystems).  
 
Methylation-Specific PCR Analysis 
  Genomic DNA from 2x106 cultured cells was isolated using the Puregene DNA 
Purification Kit (Gentra Systems, Minneapolis, PA).  Bisulfite modification of genomic DNA 
was performed using a procedure adapted from Grunau et al [230]. Genomic DNA (3 μg) 
was digested with one unit of Xho I (New England Biolabs, Beverly, MA) overnight in 12 μl 
total volume and heat inactivated at 65°C for 20 minutes; 5 μl of digest was subjected to 
bisulfite modification. Briefly, approximately 1 μg of DNA in 45 μl of distilled water was 
denatured by adding 5 μl 3 M NaOH and incubating for 20 minutes at 42°C, followed by 
addition of 450 μl of sodium bisulfite solution (saturated sodium bisulfite, 10 mM 
hydroquinone, pH 5.0) and incubation at 55°C for 4 hours. Bisulfite-modified DNA (500 μl) 
was purified using the Wizard DNA Clean-Up kit (Promega, Madison, WI), reconstituted 
with 50 μl of 1 mM Tris-Cl (pH 8.0) and desulfonated by addition of 5.5 μl 3 M NaOH and 
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incubation at 37°C for 20 minutes. The solution was neutralized by adding 40 μl 7.5 M 
ammonium acetate and precipitated with 100% ethanol at -20°C for at least 30 minutes. The 
DNA pellet was washed with 70% ethanol, dried briefly, and resuspended in 20 μl 1 mM 
Tris-Cl (pH 8.0). Bisulfite-converted DNA was used to conduct methylation-specific PCR 
(MSP) using primers that were previously described or designed using Primer3 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and directed to specific segments of the 
promoter regions and exon 1 of CST6 [129, 150], ESR1 [150, 231], and SCNNIA. The MSP 
primer sequences and thermocycling conditions for CST6, ESR1, and SCNNIA genes are 
given in Table 2.1. PCR products were fractionated on 2% agarose gels and visualized by 
ethidium bromide staining.  
 
 Statistical Analysis 
 The values for the mean and standard error of the mean (S.E.M.) were calculated 
using the statistical function of Microsoft Excel 2007.  Statistical significance was 
determined using an unpaired t-test.  Error bars depicted in bar graphs and/or indicated in 
tables represent S.E.M. of three independent experiments.   
 
Methods Related to MicroRNA Experiments in Breast Cancer Cell Lines and Primary 
Breast Cancers 
 
Cell Lines and Growth Conditions 
Human  breast  cancer  cell  lines  BT20  (ATCC#  HTB19),  BT549  (HTB122),  
Hs578T (HTB126), MCF7 (HTB22), MDA-MB-231 (HTB26), MDA-MB-415 (HTB128), 
MDA-MB-435S (HTB129), MDA-MB-436 (HTB130), MDA-MB-453 (HTB131), MDA-
MB-468  (HTB132),  SKBR3  (HTB30),  and  ZR-75-1  (CRL-1500)  were  obtained  from  
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the Tissue Culture  Core  Facility  of  the  University  of  North  Carolina  Lineberger 
Comprehensive Cancer Center  (Chapel Hill, NC). Human breast cancer cell lines SUM102, 
SUM149, and SUM185 were a gift from the laboratories of Dr. Carolyn I. Sartor 
(Department of Radiation Oncology, UNC School of Medicine, Chapel Hill, NC) and Dr. 
Stephen Ethier (Department of Pathology, Wayne State University School of Medicine, 
Detroit, MI). Human breast cancer cell line HCC1937 (CRL-2336) was a gift from the 
laboratory of Dr. William K. Kaufmann (Department of Pathology and Laboratory Medicine, 
UNC School of Medicine, Chapel Hill, NC). The normal breast epithelial cell line MCF12A 
(CRL-10782) was obtained from the ATCC (American Type Culture Collection, 
(http://www.atcc.org/). Cell lines were propagated in growth medium recommended by the 
ATCC, except for SUM102, SUM149, and SUM185 cells which were cultured in 1:1 
mixture of Dulbecco’s modified Eagle’s medium and Ham’s F12 (DMEM/F12, 
Gibco/Invitrogen Life Technologies, Carlsbad,  CA) medium supplemented with 10% horse 
serum (Gibco/Invitrogen Life Technologies), and 1% Antibiotic-Antimycotic 
(Gibco/Invitrogen Life Technologies). Growth medium was refreshed three times weekly 
unless otherwise specified for antagomir and pre-miR transfections. Cells were maintained at 
37°C and 5% CO2 (except for MDA-MB-468 which was propagated in 100% atmospheric 
air). 
 
Human Breast Tissue: Primary Breast Cancers and Normal Mammoplasty Tissue 
70 paraffin-embedded human primary breast tumors and 18 normal mammoplasty 
tissues were obtained from the paraffin archives of the UNC Lineberger Comprehensive 
Cancer Center at the University of North Carolina (Chapel Hill, NC) with the assistance of 
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Dr. Chad A. Livasy (Carolinas Medical Center, Charlotte, NC). The primary breast cancers 
included 36 luminal A, 13 luminal B, 5 HER2+, and 16 basal-like tumors. Determination of 
molecular subtype was accomplished by immunohistochemistry for ER, PR, HER2, CK5/6, 
and EGFR. Protection of patient privacy and handling of specimens followed strict policies 
of the Institutional Review Board of the University of North Carolina. 
 
RNA Extraction from Cell Lines for Gene Expression Analysis 
Total RNA for gene expression analysis and miR expression analysis was isolated 
from breast cancer cell lines, MCF12A (normal mammary epithelial cell line), and 
transfected cell lines (antagomir or pre-miR transfected) utilizing the method of 
Chomczynski and Sacchi [229] modified  for  TRIzol  Reagent  (Invitrogen  Life  
Technologies,  Carlsbad,  CA), according  to  the  manufacturer's  protocol. Nucleic acid 
samples were DNAse (Cat # M610A; Promega, Madison, WI) treated (0.02U/µl at 37ºC for 
30 minutes), and purified using the Qiagen RNeasy mini-kit (Cat # 74104; Qiagen, Valencia, 
CA). Isolated RNA was quantified after extraction using a Nanodrop Spectrophotometer 
(NanoDrop Technologies, Wilmington, DE).  
 
RNA Isolation for Real Time Analysis from Tumors and Normal Mammoplasty 
Sections 
The paraffin blocks were blinded (in terms of molecular subtypes) before selection 
for analysis and up to 35 mg of unsectioned core samples were obtained from the 
Translational Pathology Laboratory Core Facility at Department of Pathology and Laboratory 
Medicine, UNC  School of Medicine, Chapel Hill. H&E slides from all the paraffin blocks 
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were initially analyzed to select the areas of the blocks to be cored. This selection for the 
cancer blocks ensured that the cores consisted of cancer tissue, similarly for normal breast 
tissue blocks, it ensured that the cores consisted of normal breast epithelium (and not 
stroma/fat). Total RNA was isolated from breast cancers and normal breast epithelium using 
Recover All™ Total Nucleic Acid Isolation Kit for FFPE according to the manufacturer’s 
instructions (Part # 1975, Applied Biosystems).  The cores were crushed and ground in liquid 
nitrogen, and then deparaffinized using a series of washes with slide brite (instead of xylene) 
and ethanol. Pulverized tissues were suspended in 1ml of slide brite, vortexed briefly to mix 
and heated for 3 min at 50°C to melt the paraffin. The samples were centrifuged to pellet the 
tissue; slide brite was removed without disturbing the pellet and the pellet was subjected to 
two washes with 100% ethanol. After discarding the ethanol after second wash, the samples 
were subjected to additional centrifugation to get rid of any additional ethanol. The pellet 
was air-dried before digesting it in digestion buffer and protease at 50°C for three hours. 
Isolation additive was added to the samples before vortexing and mixing with 100% ethanol. 
The samples were loaded on to filter cartridges placed in collection tubes and centrifuged to 
pass the mixture through the filter. The flow through was discarded. Wash 1 and wash 2/3 
provided in the kit were used to wash through the filter. The filter assembly was centrifuged 
for additional 30 seconds to remove residual fluid from the filter. DNAse mix (10X DNAse 
buffer, DNAse, and nuclease-free water) was added to the center of each filter cartridge and 
incubated for 30 min at room temperature followed by one wash with wash 1 and two washes 
with wash 2/3. The filter assembly was centrifuged at 10,000 g for an additional minute to 
remove residual fluid from the filter. The elution solution was pre-heated to 95°C and added 
to the center of the filter. After letting it sit for at least one minute, the RNA was eluted in 
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fresh collection tube by centrifuging at maximum speed for one minute. The elution steps 
were repeated one more time to maximize the yield. Nucleic acid samples were purified 
using the Qiagen RNeasy mini-kit (Cat # 74104; Qiagen, Valencia, CA). Isolated RNA was 
quantified after extraction using a Nanodrop Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE).  
 
MicroRNA Expression Analysis 
We identified candidate miRs as potential regulators of DNMT3b using the 
computational tools of target prediction programs and resources from publicly available 
databases, including Miranda  (http://www.microRNA.org/), TargetScan 
(http://www.targetscan.org/vert_42/), miRGen 
(http://www.diana.pcbi.upenn.edu/miRGen/v3/miRGen.html), PicTar (http://pictar.mdc-
berlin.de/), and miRBase (http://microrna.sanger.ac.uk/sequences/) computing for target 
predictions based on searches using Gene symbol DNMT3b (Entrez Gene ID 1789 and 
Ensembl Gene ID ENSG00000088305). Based on high stringency in-silico selection criteria 
that included PicTar score (indicative of HMM maximum likelihood fit), highly conserved 
miRs, and good mirSVR scores (indicative of seed-site pairing, site context, free-energy, and 
conservation), we identified 25 additional miRs that potentially target DNMT3b (Figure 
2.1). We prioritized the candidate miRs based on the available literature and/or their 
recognition as potential candidates by multiple target prediction programs (Figure 2.1). miRs 
that were differentially expressed among breast cancer cells in primary tumors [216] and cell 
lines [232] were considered for further analysis. Based upon this computational analysis, we 
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selected nine miRs for examination: miR-29a, miR-29b, miR-29c, miR-148a, miR-148b, 
miR-26a, miR-26b, miR-203, and miR-222 (Figure 2.1). 
miR expression analysis was accomplished by real-time PCR utilizing an ABI 7500 
Real Time PCR System (Applied Biosystems) according to TaqMan miRNA assay protocol 
(Applied Biosystems). Total RNA samples (10 ng) were reverse transcribed using the 
TaqMan MiRNA Reverse Transcription Kit (Part # 4366596 Applied Biosystems) and 
TaqMan miRNA specific primers (Applied Biosystems) according to the manufacturer's 
protocol. Real-time primers and probes for miR-29a (Assay ID 000412), miR-29b (Assay ID 
000413), miR-29c (Assay ID 000415), miR-148a (Assay ID 000470), miR-148b (Assay ID 
000471), miR-26a (Assay ID 000405), miR-26b (Assay ID 000407), miR-203 (Assay ID 
000507), miR-222 (Assay ID 002276), and RNU66 (Assay ID 001002) were purchased from 
Applied Biosystems. These assays specifically detect mature miRNAs (not pre-miRNAs). All 
real-time PCR reactions were performed in triplicate using TaqMan Universal PCR Master 
Mix (Cat # 4324018, Applied Biosystems) in 20 µl volume containing 10 µl TaqMan 
Universal PCR Master Mix, 1 μl of primers and probe mix of the miR-specific TaqMan 
MicroRNA Assay (Applied Biosystems), 1.33 μl of RT product, and 7.67 μl of nuclease free 
water and the following amplification conditions: 95°C for 10 minutes, 40 cycles of 95°C for 
15 seconds and 60°C for 1 minute. Relative expression levels for each miR were calculated 
based upon the expression of RNU66 and differences in gene expression were determined 
relative to MCF-12A using the comparative Ct method described in the ABI Prism 7700 User 
Bulletin #2 (Applied Biosystems). 
 
Gene Expression Analysis 
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Gene expression analysis was accomplished by real-time PCR utilizing an ABI 7500 
Real Time PCR System (Applied Biosystems). Total RNA samples (2 μg) were reverse 
transcribed using the High Capacity cDNA Reverse Transcription Kit (Part # 4368814 
Applied Biosystems) according to the manufacturer's protocol. Real-time primers and probes 
for CEACAM6 (Hs00366002_m1), CDH1 (Hs00170423_m1), CST6 (Hs00154599_m1), 
DNMT3b (Hs00171876_m1), ESR1 (Hs00174860_m1), GNA11 (Hs01588833_m1), MUC1 
(Hs00159357_m1), MYB (Hs00920554_m1), SCNN1A (Hs00168906_m1), TFF3 
(Hs00173625_m1), and β-actin (Hs99999903_m1) were purchased from Applied 
Biosystems.  All real-time PCR reactions were performed in triplicate using TaqMan 
Universal PCR Master Mix (Cat # 4324018, Applied Biosystems) in 20 µl volume (10 µl 
TaqMan Universal PCR Master Mix, 1.0 µl TaqMan Real-time primers and probes, and 9 µl 
cDNA and nuclease-free water) and the following amplification conditions: 95°C for 
10 minutes, 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Relative expression 
levels for each gene were calculated based upon the expression of  β-actin for each cell line 
and differences in gene expression were determined relative to MCF-12A  in the breast 
cancer cell lines and to normal breast  tissue from reduction mammoplasties for primary 
tumors using the comparative Ct method described in the ABI Prism 7700 User Bulletin #2 
(Applied Biosystems). 
 
DNMT3b Protein Expression in Breast Cancer Cell Lines 
  Cultured breast cancer cell lines, MCF12A (normal mammary epithelial cell line), 
and transfected cell lines (antagomir or pre-miR transfected) were lysed in phosphate 
buffered saline (137 mM NaCl, 2.7 mM KCl, 8 mM Na2PO4, 2 mM KH2PO4, pH 7.4) 
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containing 0.1 mM phenylmethanesulphonylfluoride, 1 µg/ml pepstain A, 1 µg/ml leupeptin, 
1 µg/ml aprotinin, 1 mM β-glycerol phosphate, 1 mM sodium orthovanadate, and 0.1% 
Triton X-100. Cell lysates were utilized for western analysis using standard methods as 
described above in the methods related to chemotherapy experiments.   
 
Breast Cancer Cell Line Transfection with Pre-miRs 
Hypermethylator cell lines Hs578T, HCC1937, and SUM185 were selected for pre-
miR transfection with miR-148b, miR-26b, and miR-29c. These cell lines exhibit DNMT 
hyperactivity, express DNMT3b at high levels [150], and have negligible levels of expression 
of miR-26b, miR-29c, and miR-148b. All pre-miR transfections were performed in triplicate. 
Pre-miR miRNA precursors (miR-148b, PM10264; miR-26b, PM12899; and miR-29c, 
PM10518) and standard control oligomers were obtained from Applied Biosystems. For 
optimization purposes, the Pre-miR miRNA Precursor Starter Kit (Applied Biosystems) was 
utilized for the reverse transfection procedure according to manufacturer’s protocol using 
siPORT NeoFX Transfection Agent (Part # AM4510, Applied Biosystems). Four 
concentrations of transfection reagent (9µl, 12 µl, 15 µl, and 18 µl) were tested to obtain 
optimum conditions for pre-miR transfections for each cell line. Transfection reagent was 
diluted to 300 µl with opti-MEM (Gibco/Invitrogen Life Technologies), incubated for 10 
minutes at room temperature, 24 µl of 6.25 nM of Pre-miR hsa-miR-1 miRNA precursor or 
Pre-miR negative control #1 was diluted to 300 µl with opti-MEM for final concentration of 
50 nM and gently mixed with diluted transfection agent before incubating for 10 minutes at 
room temperature. The transfection complexes were dispensed into 6-well culture plates, and 
nontransfected controls were set up in parallel. 2.4 x 105 cells were transferred in 2.4 ml of 
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growth medium per well and incubated at recommended growth conditions. After 24 hrs, the 
culture medium was replaced with fresh normal growth medium. Two days after transfection, 
total RNA was extracted from transfected and control cells. The expression level of PTK9 
mRNA (target of Pre-miR miR-1 miRNA precursor) was assessed by real-time PCR 
(Hs00702289_s1, Applied Biosystems) according to the manufacturer’s instructions. Optimal 
transfection was observed with 12 µl transfection reagent in each cell line, producing 75-90% 
reduction of PTK9 mRNA after transfection with Pre-miR miR-1. Hs578T, SUM185, and 
HCC1937 cells were transfected with pre-miR precursors for miR-148b, miR-26b, and miR-
29c employing the optimized conditions. After 48 hours, total RNA was harvested for real-
time PCR analysis for miR and gene expression analyses. In addition, transfected and control 
cells were lysed for western blot analysis (as described above). 
 
Breast Cancer Cell Line Transfection with Antagomirs 
Non-hypermethylator cell lines BT20, MDA-MB-415, and MDA-MB-468 were 
selected for antagomir transfection with miR-148b, miR-26b, and miR-29c. These cell lines 
have lower DNMT activity, express DNMT3b at low levels [150], and normal levels of 
expression of miR-26b, miR-29c, and miR-148b. All antagomir transfections were performed 
in triplicate. Antagomirs (miR-148b, AM10264; miR-26b, AM12899; and miR-29c, 
AM10518) and standard control oligomers were obtained from Applied Biosystems. For 
optimization of transfection conditions, the reverse transfection procedure was performed 
using four concentrations of transfection reagent (9µl, 12 µl, 15 µl, and 18 µl), as described 
for pre-miR transfections. Transfection reagent was diluted to 300 µl with opti-MEM 
(Gibco/Invitrogen Life Technologies), incubated for 10 minutes at room temperature, 24 µl 
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of 6.25 nM of Anti-miR let-7c miRNA inhibitor positive control or Anti-miR negative 
control #1 was diluted to 300 µl with opti-MEM for final concentration of 50 nM and gently 
mixed with diluted transfection agent before incubating for 10 minutes at room temperature. 
Levels of HMGA2 mRNA (target of Anti-miR let-7c miRNA inhibitor positive control) were 
assessed by real-time PCR (Hs00171569_m1, Applied Biosystems) after RNA extraction. 
Optimal transfection was observed with 12 µl transfection reagent in each cell line, 
producing 1.8-fold to 2.4-fold increases in HMGA2 mRNA after transfection with Anti-miR 
let-7c miRNA inhibitor. BT20, MDA-MB-415, and MDA-MB-468 cells were transfected 
with antagomirs for miR-148b, miR-26b, and miR-29c and after 48 hours, total RNA was 
harvested for real-time PCR analysis for miR and gene expression analyses. In addition, 
transfected and control cells were lysed for western blot analysis (as described above). 
 
Statistical Analysis 
The values for the mean and standard error of the mean (S.E.M.) were calculated 
using the statistical function of Microsoft Excel 2007.  Statistical significance was 
determined using an unpaired t-test (two-tailed).  Error bars depicted in bar graphs represent 
S.E.M. of 3-6 independent experiments.   
  
Table 2.1. Methylation-Specific PCR Primer Sequences and Thermocycling Conditions For 
CST6, ESR1 and SCNNIA Genes 
  
Gene Methylated Unmethylated Product Size 
PCR 
Conditions 
CST6 
 
F: TCGAGTTTCGTTTTAGTTTTAGGTC 
 
R: CATAACCGTCAATACCGTCG 
F :TGAGTTTTGTTTTAGTTTTAGGTT 
 
R: CCATAACCATCAATACCATCAA 
135 
 
U:TM = 55º 
38 cycles 
M:TM = 60º 
38 cycles 
 
ESR1 
 
F: GATACGGTTTGTATTTTGTTCGC 
 
R: CGAACGATTCAAAAACTCCAACT 
F : GGATATGGTTTGTATTTGGTTTGT 
 
R: ACAAACAATTCAAAAACTCCAACT 
123 
 
TM = 58º 
35 cycles 
 
SCNN1A 
 
 
F: TTTTTTAGTTTTTTTGTTTGTTTGC 
 
R: CTCACTATCGCGAAAACGAC 
 
 
F : TTAGTTTTTTTGTTTGTTTGTGT 
 
R: AAAATCAAAACCAAAAATTTTCCA 
127 TM = 55º 38 cycles 
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miRs identified as potential candidates for regulating DNMT3b using 
computational tools and resources  (miRBase, miRGen, Pic Tar, TargetScan 
4.2 and miRanda) – 19b, 26a, 26b, 188, 203, 221, 222, 326, 330‐5p, 370, 
379, 409, 429, 519, 561, 590, 598, 618, 635, 682, 715, 765, 883b, 933, 
1253 (n=25)
miRs  that have not been analyzed 
in breast cancer or any other cancer, 
were excluded from analysis (n=13)
miRs identified by multiple 
algorithms – 26a, 26b, 203, 221, 
222, 326, 330‐5p, 370 (n=8)
miRs with differential 
expression among 
breast cancer cell
lines ‐
26a, 26b,
203, 222
(n=4)
miRs  examined: 26a, 
26b, 29a, 29b, 29c, 
148a, 148b, 203, and 
222 (n=9) 
miRs known to target  
DNMT3bmRNA: 29a, 
29b 29c, 148a and 148b  
(n=5)
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Figure 2.1. miR Regulators of  DNMT3b mRNA. Schematic illustrating the selection and 
prioritization of miR regulators of DNMT3b for analysis. Several target prediction programs 
were utilized to predict miR interactions with DNMT3b. Criteria for filtering potential 
candidates are described in the schematic. In addition to selection of candidate miR 
regulators, known regulators of DNMT3b were identified from the literature. This selection 
strategy yielded nine miRs for examination: miR-29a, miR-29b, miR-29c, miR-148a, miR-
148b, miR-26a, miR-26b, miR-203, and miR-222.  
 
  
  
RESULTS 
 
 
Results Related to Chemotherapy Experiments 
Chemosensitivity of Wild-Type Breast Cancer Cell Lines 
 The IC50 for DOX, PAX, and 5-FU have been reported for the breast cancer cell lines 
used in this study [233-235]. However, these IC50 values vary widely from laboratory to 
laboratory and with specific experimental conditions. Hence, we ascertained the IC50 for the 
drugs of interest and in the selected cell lines for the employed experimental conditions to 
establish a solid baseline for comparison. We found the MDA-MB-453 cells to be most 
sensitive to these chemotherapeutic drugs and the Hs578T cells to be most resistant (Table 
3.1). In response to DOX, MDA-MB-453 and BT549 cells exhibited similar levels of 
sensitivity, whereas Hs578T cells were relatively more resistant, displaying >2-fold higher 
IC50 compared to the other cell lines (2.7-fold greater than MDA-MB-453, 2.3-fold greater 
than BT549). Hs578T and BT549 were more resistant to PAX than MDA-MB-453 cells (IC50 
5.2-fold and 4-fold higher than MDA-MB-453). Hs578T cells displayed a 1.3-fold higher 
IC50 in response to PAX compared to BT549 cells. In response to 5-FU, BT549 and Hs578T 
cells display similar levels of resistance with 1.4-fold and 1.5-fold higher IC50 compared to 
MDA-MB-453 cells, respectively. 
 
Demethylating Treatment Sensitizes Hypermethylator Breast Cancer Cells to 
Chemotherapeutic Drugs 
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 Hypermethylator breast cancer cell lines are characterized by high rates of concurrent 
methylation-dependent silencing of multiple methylation-sensitive genes (including 
CEACAM6, CST6, ESR1, and SCNN1A) [150]. Expression of epigenetically-regulated genes 
following demethylating treatment with 5-aza was monitored to ensure that the conditions 
employed produced a biological effect. We observed re-expression of CEACAM6, CST6, 
ESR1, and SCNN1A in all three cell lines following 250 nM and 500 nM 5-aza exposure for 7 
days. The re-expression of these methylation-sensitive genes was robust and statistically 
significant for all four genes in all cell lines with 500 nM 5-aza exposure. In contrast, 250 
nM 5-aza exposure resulted in a more modest, yet statistically significant re-expression of all 
genes in Hs578T cells and statistically significant re-expression of all genes except 
CEACAM6 in MDA-MB-453 and BT549 cells. Following 250 nM 5-aza exposure, the 
MDA-MB-453 cells showed the greatest increase in CST6 expression (8-fold) followed by 
ESR1 (7.9-fold), SCNNIA (2.9-fold), and CEACAM6 (2.2-fold) (Figure 3.1a). In BT549 
cells, we observed the highest increase in SCNN1A expression (139-fold), followed by 
CEACAM6 (23-fold), CST6 (16-fold), and ESR1 (4-fold) (Figure 3.1a). Hs578T cells 
showed the greatest increase in expression of SCNN1A (118-fold) followed by ESR1 (70-
fold), CST6 (54-fold), and CEACAM6 (23-fold) (Figure 3.1a). Following 500 nM 5-aza 
exposure, the MDA-MB-453 cells demonstrated highest increase in CST6 expression (1610-
fold) followed by CEACAM6 (210-fold), SCNNIA (186-fold), and ESR1 (168-fold) (Figure 
3.1b). In BT549 cells, we observed the highest increase in SCNN1A expression (1370-fold) 
followed by CEACAM6 (559-fold), CST6 (77-fold), and ESR1 (34-fold) (Figure 3.1b). 
Hs578T cells exhibited highest increase in expression of CST6 (1099-fold) followed by 
SCNN1A (800-fold), ESR1 (488-fold) and CEACAM6 (449-fold) (Figure 3.1b). These results 
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demonstrate that the conditions for demethylating treatment utilized produced significant 
alterations in gene expression profile, including re-expression of these methylation-sensitive 
genes in hypermethylator cells. 
 Following pretreatment of the breast cancer cell lines with 5-aza, we observed no 
discernible changes in cell morphology or cell proliferation rate compared to the untreated 
controls. While pretreatment with 5-aza clearly produced alterations in gene expression, no 
evidence of 5-aza related toxicity was observed in this study (with either 250 nM or 500 nM 
5-aza). To determine if demethylating treatment sensitizes hypermethylator cells to cytotoxic 
chemotherapy, we compared cell kill after 5-aza pretreatment to that in control cells. The 
results show that 5-aza pretreatment sensitizes the hypermethylator breast cancer cells to 
DOX, PAX, and 5-FU, and that the improved sensitivity is a function of dose and duration of 
exposure to 5-aza. Pretreatment of cells with 250 nM 5-aza or 500 nM 5-aza for 3 days did 
not increase the sensitivity of breast cancer cells to DOX. Likewise, pretreatment with 250 
nM 5-aza for 7 days did not increase sensitivity of MDA-MB-453 and Hs578T cells to any of 
the drugs evaluated (Table 3.1). However, 7 days pretreatment with 250 nM 5-aza sensitized 
BT549 cells, reducing the IC50 for DOX by 32% (Figure 3.2a), for PAX by 24%, and for 5-
FU by 46% (Table 3.1).  In contrast, pretreatment with 500 nM 5-aza for 7 days significantly 
improved the sensitivity of each breast cancer cell line to DOX, PAX, and 5-FU 
(representative dose-response curves are shown in Figure 3.2). Increased sensitivity 
following pretreatment with 500 nM 5-aza observed with each cell line (and 250 nM 5-aza in 
BT549) was detected at all the employed doses of three drugs (Table 3.1). MDA-MB-453 
cells showed reduction in IC50 for DOX (0.086 µM to 0.034 µM; 60% reduction), PAX 
(0.497 nM to 0.311 nM; 37%), and 5-FU (0.817 mM to 0.065 mM; 90%); BT549 cells 
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demonstrated reduction in IC50 for DOX (0.099 µM to 0.052 µM; 47% reduction), PAX 
(1.974 nM to 1.015 nM; 48%), and 5-FU (1.183 mM to 0.472 mM; 60%); Hs578T cells also 
exhibited a reduction in IC50 for DOX (0.230 µM to 0.110 µM; 52% reduction, PAX (2.605 
nM to 1.466 nM; 43%), and 5-FU (1.211 mM to 0.0.371 mM; 69%). The greatest reduction 
in IC50 (reflecting greatest improvement of sensitivity, with 5-aza treatment) was observed 
with 5-FU (60-92%), followed by DOX (47-60%), and PAX (37-48%) (Table 3.1).  
 Increased drug sensitivity following pretreatment with 250 nM 5-aza was observed 
only in BT549 cells. This responsiveness appears to correlate with the levels of DNMT3b 
expressed in BT549 cells compared to MDA-MB-453 and Hs578T cells. Previous studies 
established that among these breast cancer cell lines, MDA-MB-453 cells exhibit the highest 
levels of DNMT3b protein and BT549 cells express the lowest levels [150]. These 
observations suggest that 250 nM 5-aza was sufficient to target the comparatively lower 
levels of DNMT3b seen in BT549 cells (Figure 3.2a), but was insufficient to exert 
significant effects in MDA-MB-453 and Hs578T cells with higher DNMT3b levels (Figure 
3.2b-c; Table 3.1).  
 
DNMT3b Knockdown Sensitizes Hypermethylator Breast Cancer Cell Lines to 
Chemotherapeutic Drugs 
 DNMT3b protein levels in wild-type breast cancer cell lines and transfected cell lines 
(transfected with pLVTHMDNMT3b or pLVTHMSCRAM) were evaluated by western blot 
analyses. Significant levels of DNMT3b protein were detected for each of the wild-type 
breast cancer cell lines (Figure 3.3a). MDA-MB-453 cell lines expressed the highest levels 
of DNMT3b protein followed by Hs578T cells, and BT549 cells expressed lowest levels of 
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DNMT3b protein (Figure 3.3b). Transfection with pLVTHMSCRAM had no effect on 
DNMT3b expression levels, in contrast, each of the DNMT3b KD cell lines demonstrated 
significant alteration of DNMT3b protein levels, reflecting >90% knockdown (Figure 3.3c). 
Subsequently, wild-type breast cancer cell lines, scrambled controls, and DNMT3b KD cells 
were examined for expression of methylation-sensitive genes (CEACAM6, CST6, ESR, and 
SCNN1A). Gene expression levels for each of these genes were low in the wild-type breast 
cancer cell lines and in scrambled-control cell lines. However, each of these methylation-
sensitive genes was found to be re-expressed in DNMT3b KD cell lines (Figure 3.4). The 
MDA-MB-453 DNMT3b KD cells had statistically significant re-expression of SCNN1A (6-
fold), and ESR1 (6-fold) (Figure 3.4a). In BT549 DNMT3b KD cells, we observed 
statistically significant re-expression of CST6 (13-fold), ESR1 (6-fold), and SCNN1A (4-fold) 
(Figure 3.4b). Hs578T DNMT3b KD cells exhibited statistically significant re-expression of 
CST6 (310-fold), ESR1 (261-fold), SCNN1A (30-fold), and CEACAM6 (17-fold) (Figure 
3.4c). Methylation-specific PCR analysis showed changes in the methylation status of select 
methylation-sensitive genes after knocking down expression of DNMT3b. We observed that 
MDA-MB-453 cells contain only methylated alleles for CST6, ESR1, and SCNN1A (Figure 
3.5), whereas MDA-MB-453 cells after DNMT3b knockdown contain both methylated and 
unmethylated alleles (Figure 3.5). Comparable results were seen in Hs578T cells and 
Hs578T cells after DNMT3b knockdown (Figure 3.5). BT549 cells and BT549 cells after 
DNMT3b knockdown showed similar results for CST6 (Figure 3.5) and ESR1. These 
observations combine to suggest that DNMT3b KD in these breast cancer cell lines partially 
or completely corrects the hypermethylation defect resulting in alteration of gene-specific 
promoter methylation and re-expression of methylation-sensitive genes. 
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 To evaluate the effects of DNMT3b KD on the sensitivity of breast cancer cells to 
standard drug regimens, we compared the response to chemotherapeutics in wild-type 
hypermethylator breast tumor cells to the response in cells after RNAi-mediated knockdown 
of DNMT3b (Figure 3.6). Scrambled control cell lines exhibited IC50 values for each of the 
drugs tested that were comparable to values for the wild-type breast cancer cell lines (Table 
3.1). In MDA-MB-453 DNMT3b KD cells, we observed 44% reduction in DOX IC50 (0.086 
µM to 0.048 µM), 24% reduction for PAX (0.497 nM to 0.376 nM) (Figure 3.6b), and 82% 
reduction for 5-FU (0.817 mM to 0.145 mM) (Table 3.1). In BT549 DNMT3b KD cells, we 
observed 13% reduction in DOX IC50 (0.099 µM to 0.086 µM) (Figure 3.6a), 16% reduction 
for PAX (1.974 nM to 1.660 nM), and 33% reduction for 5-FU (1.183 mM to 0.791 mM) 
(Table 3.1). Hs578T DNMT3b KD cells exhibited 32% reduction in IC50 for DOX (0.230 
µM to 0.155 µM), 29% reduction for PAX (2.605 nM to 1.839 nM), and 53% reduction for 
5-FU (1.211 mM to 0.562 mM) (Table 3.1, Figure 3.6c). Overall, the greatest reduction in 
IC50 was observed with 5-FU (33-82%), followed by DOX (13-44%), and PAX (16-29%) 
(Table 3.1). These results demonstrate that knocking down DNMT3b in hypermethylator 
breast cancer cells increases the effectiveness of chemotherapeutic drugs.  
 
5-Aza Enhances Chemosensitivity in Breast Cancer Cell Lines After DNMT3b 
Knockdown 
 To analyze the combined effects of DNMT3b KD and demethylating treatment, we 
subjected the DNMT3b KD cell lines to 250 nM and 500 nM 5-aza for 7 days and then 
evaluated cell kill after exposure to chemotherapeutic drugs (Figure 3.7). We observed 
increased sensitivity of DNMT3b KD cells to DOX, PAX, 5-FU following 500 nM 5-aza 
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pretreatment for 7 days (Table 3.1). However, 250 nM 5-aza pretreatment for 7 days led to 
increased sensitivity to chemotherapeutics only in BT549 DNMT3b KD cells (Table 3.1, 
Figure 3.7a). MDA-MB-453 DNMT3b KD and Hs578T DNMT3b KD cells exhibited 
comparable IC50s with/without pre-treatment with 250 nM 5-aza for 7 days. In MDA-MB-453 
DNMT3b KD cells, we observed 59% reduction in DOX IC50 (0.086 µM to 0.035 µM), 37% 
reduction for PAX (0.497 nM to 0.313 nM), and 92% reduction for 5-FU (0.817 mM to 
0.067 mM) (Figure 3.7c) post-5-aza exposure (Table 3.1). In BT549 DNMT3b KD cells, we 
observed 32% reduction for DOX IC50 (0.065 µM to 0.086 µM), 23% reduction in PAX 
(1.974 nM to 1.527 nM), and 46% reduction for 5-FU (1.183 mM to 0.632 mM) after 250 
nM 5-aza exposure for 7 days. However, with 500 nM 5-aza exposure for 7 days, BT549 
DNMT3b KD cells demonstrated 45% reduction in DOX IC50 (0.099 µM to 0.054 µM) 
(Figure 3.7a), 45% reduction for PAX (1.974 nM to 1.082 nM), and 60% reduction for 5-FU 
(1.183 mM to 0.470 mM) (Table 3.1). In Hs578T DNMT3b KD cells, there was a 51% 
reduction in IC50 for DOX (0.230 µM to 0.111 µM), 53% reduction for PAX (2.605 nM to 
0.573 nM) (Figure 3.7b), and 70% reduction for 5-FU (1.211 mM to 0.359 mM) drugs after 
500 nM 5-aza pre-treatment (Table 3.1). These results demonstrate that pre-treatment of 
DNMT3b KD breast cancer cells with demethylating agents increases the effectiveness of 
chemotherapeutic drugs. Interestingly, the increased sensitivity observed after knocking 
down DNMT3b in these cell lines and further treating them with 500 nM 5-aza (and 250 nM 
5-aza in BT549 cells) was comparable to the increased sensitivity seen in wild-type cells 
after demethylating treatment alone (representative examples are shown in Figure 3.8). This 
effect may reflect the targeting of other DNA methyltransferases (DNMT1 and/or DNMT3a) 
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by 5-aza. In addition, this effect could be related to 5-aza-mediated inhibition of residual 
DNMT3b activity.  
 
Results Related to MicroRNA Experiments in Breast Cancer Cell Lines 
Hypermethylator Breast Cancer Cell Lines Express Diminished Levels of Regulatory 
miRs 
  Previous investigations identified a hypermethylation defect in a subset of breast 
cancer cell lines [150]. Hypermethylator cell lines display DNMT hyperactivity and 
overexpression of DNMT3b, in contrast to non-hypermethylator cell lines [150]. In this 
study, we investigated possible molecular mechanisms governing DNMT3b overexpression 
in hypermethylator cell lines, with a focus on miR-mediated regulation of DNMT3b. Hence, 
we examined the levels of expression of select miRs that are known or predicted to regulate 
DNMT3b (miR-26a, miR-26b, miR-29a, miR-29b, miR-29c, miR-148a, miR-148b, miR-203, 
and miR-222) among breast cancer cell lines that differentially express DNMT3b. Ten of 
these cell lines express the hypermethylation defect (BT-549, HS578T, HCC1937, MDA-
MB-231, MDA-MB-435S, MDA-MB-436, MDA-MB-453, SUM102, SUM149, and 
SUM185) and six are non-hypermethylators (BT-20, MCF-7, MDA-MB-415, MDA-MB-
468, SK-BR-3, and ZR-75-1) ([150, 236] and unpublished observations). Differential levels 
of miR expression were observed for six of the nine miRs evaluated, including miR-26a, 
miR-26b, miR-29c, miR-148a, miR-148b, and miR-203 (Figure 3.9). While there was 
variability in expression among the miRs examined, in general the hypermethylator cell lines 
expressed diminished levels compared to the non- hypermethylator cell lines (Figure 3.10a-
f). miR-29a, miR-29b, and miR-222 did not display the pattern of expression observed with 
the majority of miRs. miR-29a and miR-29b were expressed at similar levels among breast 
76 
 
cancer cell lines irrespective of their methylation status. The lack of differential expression of 
these miRs is evident from a comparison of average levels in hypermethylator and non-
hypermethylator cell lines (Figure 3.9). In contrast to the pattern observed with other miRs, 
the average expression of miR-222 among hypermethylator cell lines was higher than in non-
hypermethylator cell lines. This is consistent with the suggestion that miR-222 functions as 
an oncogenic miR [237, 238]. 
The average expression of miR-148a, miR-148b, miR-26a, and miR-26b among 
hypermethylator cell lines was significantly diminished compared to the average expression 
of these miRs among non-hypermethylator cell lines (p<0.05) (Figure 3.9). 10/10 (100%) of 
hypermethylator cell lines expressed low levels of miR-148b, and 5/6 (83%) of non-
hypermethylator cell lines express higher levels of miR-148b (except BT20; Figure 3.10c).  
Likewise, miR-148a is expressed at low levels in 9/10 (90%) of hypermethylator cell lines 
(except MDA-MB-453) and the majority of non-hypermethylator cell lines (5/6, 83%) 
express miR-148a at higher levels (except MCF7; Figure 3.10b).  8/10 (80%) of 
hypermethylator cell lines display low levels of miR-26a expression (except Hs578T and 
MDA-MB-453), whereas all non-hypermethylator cell lines (6/6, 100%) express higher 
levels of miR-26a (Figure 3.10d). Similarly, 9/10 (90%) hypermethylator cell lines express 
low levels of miR-26b (except MDA-MB-453), and 5/6 (83%) of non-hypermethylator cell 
lines express higher levels of miR-26b (except BT20; Figure 3.10e). Differences in average 
expression of miR-29c and miR-203 in hypermethylator cell lines versus non-
hypermethylator cell lines were not statistically significant (Figure 3.9), although there was a 
distinct trend towards lower expression in the hypermethylator cell lines (p=0.15 and 
p=0.19). 6/10 (60%) of hypermethylator cell lines expressed low levels of miR-29c (except 
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MDA-MB-231, MDA-MB-436, MDA-MB-453, and BT549) and 5/6 (83%) of non-
hypermethylator cell lines demonstrated higher levels of miR-29c (except MCF7; Figure 
3.10a). The expression of miR-203 was low in both hypermethylator and non-
hypermethylator cell lines, but with differential expression levels (Figure 3.10f). 7/10 (70%) 
of hypermethylator cell lines expressed miR-203 at low or undetectable levels (except MDA-
MB-453, SUM149, and HCC1937), while 5/6 (83%) of non-hypermethylator cell lines 
expressed miR-203 at easily detectable levels (except SK-BR-3).   
 
Diminished Expression of miR-29c, miR-148a, miR-148b, miR-26a, miR-26b, and miR-
203 Predict Hypermethylator Status Among Breast Cancer Cell Lines 
  We observed differential expression of miR-26a, miR-26b, miR-29c, miR-148a, miR-
148b, and miR-203 among breast cancer cell lines with strong trends towards diminished 
expression in hypermethylators compared to non-hypermethylator cell lines (Figure 3.9). To 
evaluate the value of individual miR expression levels in the prediction of the methylation 
status of a given breast cancer cell line, a Bayesian analysis was performed. Threshold values 
were determined for each of the differentially expressed miRs using correct assignments 
(CA) as a guiding principle. These threshold values are indicated in Figure 3.10a-f. The 
expression levels of five miRs emerged as excellent individual predictors of methylator status 
among breast cancer cell lines: miR-148b (CA=94%), miR-26b (CA=94%), miR-148a (CA= 
88%), miR-26a (CA=88%), and miR-203 (CA=81%) (Table 3.2). These miRs individually 
displayed excellent sensitivity (range: 80-100%) and specificity (range: 83-100%), as well as 
excellent positive predictive value (PPV range: 89-100%) and negative predictive value 
(NPV range: 71-100%) (Table 3.2).  The best threshold value for miR-29c produced 
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CA=69% (sensitivity=60%, specificity=83%, PPV=86%, and NPV=56%) (Table 3.2). The 
remaining miRs displayed poor predictive value for determination of methylation status of 
breast cancer cell lines (Table 3.2).  
 
miR Expression Patterns and miR Scores for Hypermethylator and Non-
Hypermethylator Breast Cancer Cell Lines 
  Six regulatory miRs were chosen for further analysis based on excellent 
characteristics related to prediction of methylation status (CA, sensitivity, specificity, PPV, 
and NPV) among hypermethylator and non-hypermethylator breast cancer cell lines, 
including miR-29c, miR-148a, miR-148b, miR-26a, miR-26b, and miR-203. miR scores 
were generated for each breast cancer cell line, reflecting the number of miRs with 
diminished expression. Hypermethylator breast cancer cell lines frequently express 
diminished levels of this panel of miRs. 9/10 (90%) of hypermethylator cell lines express >5 
miRs at diminished levels (Figure 3.11a), resulting in higher miR scores. The exception to 
this is MDA-MB-453, which expresses low levels of miR-148b only (Figure 3.10c). Hence, 
MDA-MB-453 has a low miR score reflecting higher levels of expression of the majority of 
miRs examined (Figure 3.11a). Three hypermethylator cell lines (MDA-MB-435s, SUM102, 
and SUM185) express diminished levels of all six miRs examined (Figure 3.11a). In contrast 
to the hypermethylator cell lines, non-hypermethylator cell lines typically express the 
majority of this panel of miRs at higher levels. 5/6 (83%) of non-hypermethylator cell lines 
express ≥5 miRs at higher levels (Figure 3.11b), resulting in lower miR scores. The 
exception was MCF7, which expresses low levels of miR-29c and miR-148a (Figure 3.10a-
b). Three non-hypermethylator cell lines (MDA-MB-415, MDA-MB-468, and ZR-75-1) 
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expressed higher levels of all six miRs in this panel (Figure 3.11b). Hypermethylator breast 
cancer cell lines exhibit an average miR score of 4.9 ± 0.46, whereas, non-hypermethylator 
cell lines exhibit an average miR score of 0.67 ± 0.33 (p<0.0001).  
 
miR Score Correlates With Gene Expression Score and Promoter Methylation Score    
A linear correlation analysis was performed to determine if miR score significantly 
associates with methylation score and expression score for each breast cancer cell line. 
Methylation score and expression score reflect the combined relative promoter methylation 
status and the combined relative gene expression status for methylation-sensitive biomarker 
genes associated with the hypermethylation defect (CEACAM6, CDH1, CST6, ESR1, 
GNA11, MUC1, MYB, TFF3, and SCNNIA) [150]. A strong inverse correlation (r=-0.66, 
p=0.0056) was observed between miR score and gene expression score (Figure 3.12a). 
Breast cancer cell lines that exhibit diminished expression of multiple regulatory miRs (high 
miR score) tend to express low levels of methylation-sensitive genes (gene expression score) 
and cell lines that express higher levels of regulatory miRs (low miR score) tend to express 
methylation-sensitive genes at higher levels (Figure 3.12a). A strong correlation (r=0.72, 
p=0.002) was observed between miR score and methylation score (Figure 3.12b).  Breast 
cancer cell lines that exhibit diminished expression of multiple regulatory miRs (high miR 
score) exhibit higher methylation scores and cell lines that express higher levels of regulatory 
miRs (low miR score) tend to have lower methylation scores (Figure 3.12b). Previous 
studies demonstrated significant relationships between overexpression of DNMT3b and gene 
expression scores and methylation scores for methylation-sensitive genes [150].  The current 
results strongly support the suggestion that loss of miR expression may account for the 
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DNMT3b-mediated hypermethylation defect among breast cancer cell lines that is 
characterized by methylation-dependent loss expression of methylation-sensitive biomarker 
genes. 
 
Co-regulation of miR Expression in Breast Cancer Cell Lines 
  To determine if miRs that regulate DNMT3b are independently regulated or co-
regulated at the level of expression, a linear correlation analysis was performed to examine 
patterns of miR expression among hypermethylator and non-hypermethylator breast cancer 
cell lines. Statistically significant linear relationships were observed between the levels of 
expression of several miRs (Figure 3.13a-f): miR-26a and miR-26b (r=0.92, p<0.0001), 
miR-148a and miR-26a (r=0.88, p<0.0001), miR-148a and miR-26b (r=0.85, p<0.0001), 
miR-29c and miR-148a (r=0.81, p=0.0002), miR-148a and miR-148b (r=0.83, p<0.0001), 
and miR-29c and miR-148b (r=0.92, p<0.0001). In addition, significant linear relationships 
were observed for expression of miR-26a and miR-203 (r=0.71, p=0.0019), miR26b and 
miR-203 (r=0.68, p=0.038), miR-26a and miR-29c (r=0.60, p=0.014), miR-148a and miR-
203 (r=0.60, p=0.014), and miR-26b and miR-148b (r=0.5, p=0.04).  No significant linear 
relationships were observed for expression of miR-26b and miR-29c, miR-148c and miR-
203, or miR-29c and miR-203. Combined, these observations suggest that several miRs that 
function in the regulation of DNMT3b are co-regulated. 
 
Changes in miR Expression Levels in Hypermethylator and Non-Hypermethylator 
Breast Cancer Cell Lines after Pre-miR and Antagomir Transfection  
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To determine the mechanistic role of specific miRs in the dysregulation of DNMT3b 
among breast cancer cell lines, the complementary approach of modulating miR levels by 
transfection of pre-miR precursors (to enforce miR expression in cells lacking a given miR) 
or transfection of antagomirs (to knock down miR expression in cells that express normal 
levels of a given miR) was employed. Transfection of hypermethylator cell lines Hs578T, 
HCC1937, and SUM185 with pre-miR precursors for miR-148b, miR-26b, and miR-29c 
resulted in restoration of expression of these miRs (Figure 3.14a-c). Following pre-miR 
transfection, Hs578T cells displayed 210-fold, 160-fold, and 240-fold increased levels of 
miR-148b, miR-26b, and miR-29c (Figure 3.14a).  Likewise, pre-miR transfection produced 
430-fold, 2,100-fold, and 580-fold increases in miR-148b, miR-26b, and miR-29c levels in 
HCC1937 cells (Figure 3.14b), and 54,000-fold, 4,700-fold, and 2,200-fold increases in 
miR-148b, miR-26b, and miR-29c levels in SUM185 cells (Figure 3.14c). Non-target 
control pre-miR precursors did not produce any significant increase in miR-148b, miR-26b, 
and miR-29c levels in any of these cell lines (Figure 3.14a-c). 
Transfection of non-hypermethylator cell lines BT20, MDA-MB-415, and MDA-MB-
468 with antagomirs directed against miR-148b, miR-26b, and miR-29c resulted in a 
significant knockdown of miR-148b, miR-26b, and miR-29c levels (Figure 3.15a-c). 
Antagomir transfection of BT20 cells resulted in reduction of miR-148b, miR-26b, and miR-
29c levels by 76%, 69%, and 73%, respectively (Figure 3.15a). Likewise, antagomir 
transfection of MDA-MB-415 cells produced 76%, 49%, and 48% reductions in miR-148b, 
miR-26b, and miR-29c levels (Figure 3.15b), and antagomir transfection of MDA-MB-468 
cells resulted in 72%, 69%, and 35% reduction in miR-148b, miR-26b, and miR-29c levels 
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(Figure 3.15c).  Non-target control antagomirs did not produce significant alterations in the 
level of miR-148b, miR-26b, and miR-29c in any of these cell lines (Figure 3.15a-c). 
 
Perturbation of Regulatory miR Expression Alters DNMT3b Levels in 
Hypermethylator and Non-Hypermethylator Breast Cancer Cell Lines 
Enforced expression of miR-148b, miR-26b, and miR-29c in hypermethylator cell 
lines Hs578T, HCC1937, and SUM185 resulted in statistically significant reduction in 
DNMT3b expression levels (Figure 3.16). In Hs578T cells, miR-29c expression reduced 
DNMT3b levels by 73%, and expression of miR-148b and miR-26b produced 62% reduction 
in DNMT3b levels (Figure 3.16). Similar results were obtained in HCC1937 cells with 58%-
64% reductions of DNMT3b levels in response to enforced expression of miR-148b, miR-
26b, and miR-29c (Figure 3.16). The most dramatic effect of enforced pre-miR expression 
on DNMT3b levels was observed in SUM185 cells.  Expression of miR-29c in SUM185 cells 
resulted in an 88% decrease in DNMT3b mRNA (Figure 3.16).  Likewise, expression of 
miR-148b and miR-26b in SUM185 cells produced 80% and 82% reduction in DNMT3b 
levels (Figure 3.16). Transfection of non-target control pre-miR precursors did not produce 
any significant change in DNMT3b levels in Hs578T, HCC1937, and SUM185 cells (Figure 
3.16). Western analysis of cell lysates from Hs578T, HCC1937, and SUM185 cells following 
pre-miR transfection failed to detect significant alterations in DNMT3b protein levels, 
probably due to the transient nature of this assay system. Likewise, assessment of 
methylation-sensitive gene expression (for CEACAM6, CST6, and SCNN1A) in Hs578T cells 
after enforced expression of miR-148b, miR-26b, and miR-29c did not reveal changes in 
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levels of expression compared to control cells, consistent with the lack of change in 
DNMT3b protein levels.  
Antagomir-mediated knockdown of miR-148b, miR-26b, and miR-29c in non-
hypermethylator cell lines MDA-MB-468, MDA-MB-415, and BT20 resulted in statistically 
significant increases in DNMT3b expression levels (Figure 3.17). The most dramatic effects 
were observed in MDA-MB-468 cells, where miR-148b knockdown produced a 3.2-fold 
increase in DNMT3b mRNA, whereas knockdown of miR-26b and miR-29c resulted in 2-
fold and 2.6-fold increases in DNMT3b levels, respectively (Figure 3.17). Comparable 
increases in DNMT3b expression levels (1.8-fold to 2-fold) were observed in BT20 cells 
following knockdown of miR-148b, miR-26b, and miR-29c (Figure 3.17).  More modest 
increases of DNMT3b levels (1.2-fold to 1.4-fold) were observed in MDA-MB-415 cells after 
knockdown of miR-148b, miR-26b, and miR-29c; though modest, these alterations were 
statistically significant.  Transfection of non-target control antagomirs did not produce any 
significant change in DNMT3b levels in these cell lines (Figure 3.17). Similar to the results 
obtained with pre-miR-transfected hypermethylator cell lines, western analysis of cell lysates 
from MDA-MB-468, MDA-MB-415, and BT20 cells following antagomir transfection failed 
to detect significant alterations in DNMT3b protein levels. Further, assessment of 
methylation-sensitive gene expression (for CEACAM6, CST6, and SCNN1A) in MDA-MB-
468 cells after antagomir-mediated knockdown of miR-148b, miR-26b, and miR-29c did not 
reveal changes in levels of expression compared to control cells, consistent with the lack of 
change in DNMT3b protein levels in this short-term assay system. 
 
Results  Related to MicroRNA Analysis in Primary Breast Cancers 
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Hypermethylator Breast Cancer Cells Express Diminished Levels of Regulatory miRs 
We utilized a cohort of 70 primary human breast cancers of known molecular subtype 
(36 luminal A, 13 luminal B, 5 Her2+, 16 basal-like) and 18 normal mammoplasty tissues to 
analyze expression of microRNAs that contribute to regulation of DNMT3b (miR-26a, miR-
26b, miR-29a, miR-29b, miR-29c, miR-148a, miR-148b, miR-203, and miR-222). Average 
miR expression in each of the intrinsic subtypes of breast cancer is shown in the Table 3.3. 
Significantly reduced average expression of miR-29c distinguished basal-like breast cancers 
from other molecular subtypes (Table 3.3). The average expression of miR-26a was also 
reduced in basal-like breast cancers compared to its expression in other subtypes of primary 
breast cancers, but the difference was not statistically significant (Table 3.3).  
The methylation status of a subset of 33 cancers (6 luminal A, 6 luminal B, 5 HER2+, 
and 16 basal-like cancers) was established through examination of methylation-sensitive 
biomarker gene expression. Individual cancers were classified as hypermethylators when 
their expression signature reflected diminished levels of ≥ 7 biomarker genes. Among this 
cohort of 33 cancers, 12 (36%) were classified as hypermethylators (Figure 3.18). 9/12 
(75%) hypermethylator cancers corresponded to basal-like molecular subtype, and this 
hypermethylator group contains 56% (9/16) of all basal-like cancers examined (Figure 3.19). 
The remaining hypermethylator cancers corresponded to the luminal A (n=1), luminal B 
(n=1), and HER2+ (n=1) subtypes. This finding is consistent with the observation of a large 
degree of correspondence and overlap between basal-like cancers and hypermethylator breast 
cancers. The miR expression status within this subset of 33 cancers is shown in Figure 3.20.    
We compared the expression patterns of the miRs between the two subsets of basal-
like breast cancers; hypermethylators (n=9, 56%) and non-hypermethylators (n=7, 44%). 
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While there was variability in expression among the miRs examined, in general the 
hypermethylator cancers expressed diminished levels of regulatory miRs compared to the 
non-hypermethylator cancers (Figure 3.19). miR-29c did not display the pattern of 
expression observed with the majority of miRs. Since loss of miR-29c differentiated the 
basal-like cancers from other subtypes of breast cancers, the absence of differential 
expression among the basal-like cancers suggests that loss of miR-29c to be a feature of this 
molecular subtype, irrespective of the methylator status. 
The average expression of miR-29a and miR-26a among hypermethylator basal-like 
cancers was significantly diminished compared to the average expression of these miRs 
among non-hypermethylator basal-like cancers (p<0.05) (Figure 3.21). Differences in 
average expression of miR-29b and miR-26b in hypermethylator cancers versus non-
hypermethylator cancers were not statistically significant (Figure 3.21), although there was a 
distinct trend towards lower expression in the hypermethylator tumors (p=0.11 and p=0.08). 
9/9 (100%) hypermethylator cancers expressed low levels of miR-29b, miR-26a, and miR-
26b, and 8/9 (89%) of these expressed low levels of miR-29a (Figure 3.22a-d). However, 
among non-hypermethylator cancers, miR-29a and miR-26a were normally expressed in 4/7 
(57%) cancers, and miR-29b and miR-26b were expressed at normal levels in 3/7 (43%) non-
hypermethylator cancers (Figure 3.22a-d). Interestingly, the three non-hypermethylator 
cancers with low levels of expression of miR-29a exhibited low levels of expression of miR-
26a, miR-29b, and miR-26b. In addition, these three cancers express low levels of miR-148b 
and miR-203. miR-29c is expressed at normal levels in 3/7 (43%) non-hypermethylator 
cancers. However, the 4 non-hypermethylator cancers with diminished miR-29c do not 
include all three cancers that lost the expression of multiple miRs (Figure 3.22e). Among 
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hypermethylator cancers, 6/9 (67%) expressed low levels of miR-29c (Figure 3.22e). 7/9 
(78%) and 8/9 (89%) cancers had diminished levels of expression of miR-148a and miR-
148b respectively (Figure 3.22f-g). These miRs were expressed at normal levels in 5/7 (71%, 
miR-148a) and 4/7 (57%, miR-148b) non-hypermethylator cancers (Figure 3.22f-g). 7/9 
(78%) hypermethylator cancers expressed miR-203 at low levels, while 3/7 (43%) non-
hypermethylator cancers expressed miR-203 at easily detectable levels (Figure 3.22h).  miR-
222 was expressed at low levels in 5/9 (56%) hypermethylator cancers. 6/7 (87%) non-
hypermethylator cancers expressed miR-222 at normal levels (Figure 3.22i). 
 
Diminished Expression of miR-29a, miR-29b, miR-26a, miR-26b, miR-148a, and miR-
148b Predict Hypermethylator Status Among Breast Cancers 
We observed differential expression of miR-29a, miR-29b, miR-26a, miR-26b, miR-
148a, and miR-148b among basal-like breast cancers with strong trends towards diminished 
expression in hypermethylators compared to non-hypermethylator cancers. To assess the 
value of individual miR expression levels in the prediction of the methylation status of a 
certain tumor, a Bayesian analysis was performed. Correct assignments (CA) were used as a 
guiding principle to determine the threshold values for each of the differentially expressed 
miRs indicated in Figure 3.22. The expression level of miR-26a (CA=81%) emerged as the 
best individual predictor of methylator status among basal-like breast cancers, followed by 
miR-29a (CA=75%), miR-29b (CA=75%), miR-26b (CA=75%), miR-148a (CA=75%), and 
miR-148b (CA=75%). These miRs individually displayed excellent sensitivity (range: 78-
100%) and negative predictive value (NPV range: 71-100%), as well as good specificity 
(range: 43-71%) and positive predictive value (PPV range: 69-78%).  The remaining miRs 
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displayed poor predictive value for determination of methylation status among breast cancers 
(CA=63%-69) (Table 3.4).  
 
miR Scores Correlate With Methylation-sensitive Gene Expression Scores Among 
Primary Breast Cancers 
 miR scores were generated for each breast cancer, reflecting the number of miRs 
with diminished expression. Hypermethylator basal-like breast cancers frequently express 
diminished levels of this panel of miRs. 8/9 (89%) hypermethylator basal-like cancers 
express >6 regulatory miRs at diminished levels (Figure 3.23), resulting in higher miR 
scores. Three hypermethylator cancers express diminished levels of all nine miRs examined 
(Figure 3.23). In contrast to the hypermethylator cancers, non-hypermethylator basal-like 
breast cancers typically express the majority of these regulatory miRs at higher levels. 4/7 
(57%) non-hypermethylator cancers express >7 miRs at higher levels (Figure 3.23), resulting 
in lower miR scores. Hypermethylator basal-like cancers exhibit an average miR score of 7.6 
± 0.5, whereas, non-hypermethylator basal-like cancers exhibit an average miR score of 4 ± 
1.3 (p=0.039).  
A linear correlation analysis was performed to determine if miR scores significantly 
correlate with the expression score among basal-like breast cancers. The expression score 
reflects the combined relative gene expression status for methylation-sensitive biomarker 
genes associated with the hypermethylation defect (CEACAM6, CDH1, CST6, ESR1, 
GNA11, MUC1, MYB, TFF3, and SCNNIA) [150]. A strong inverse correlation (r=-0.67, 
p=0.003) was observed between miR score and gene expression score (Figure 3.24). The 
cancers that exhibit diminished expression of multiple regulatory miRs (high miR score) tend 
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to express low levels of methylation-sensitive genes (gene expression score) and cancers that 
express higher levels of regulatory miRs (low miR score) tend to express methylation-
sensitive genes at higher levels (Figure 3.24). Previous studies demonstrated significant 
relationships between overexpression of DNMT3b and gene expression scores for 
methylation-sensitive genes [150].  miR expression patterns revealed two groups among 
basal-like breast cancers corresponding to low expression (n=11) and high expression (n=5) 
(Figure 3.25). The subset of basal-like breast cancers with reduced expression overlaps 
considerably with the hypermethylator subset of basal-like breast cancers. 8/9 
hypermethylators correspond to the low expression group. These results strongly support the 
suggestion that loss of miR expression may account for the expression of hypermethylation 
defect that is characterized by DNMT3b-overexpression.  
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Table 3.2. Bayesian Analyses Show That Loss of miR Expression is Associated with 
Expression of Hypermethylation Defect in Breast Cancer Cell Lines. Threshold values for 
Bayesian analysis are as follows: miR-29a, 1.0; miR-29b, 0.15; miR-29c, 0.62; miR-148a, 
2.8, miR-148b, 6.0; miR-26a, 4.0; miR-26b, 3.63; miR-203, 0.2; and miR-222, 2.0. 
  
 
 Sensitivity Specificity 
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
Correct 
Assignment 
miR-29a 60% 66% 75% 50% 63% 
miR-29b 60% 66% 75% 50% 63% 
miR-29c 60% 83% 86% 56% 69% 
miR-148a 90% 83% 90% 83% 88% 
miR-148b 100% 83% 91% 100% 94% 
miR-26a 80% 100% 100% 75% 88% 
miR-26b 90% 100% 100% 86% 94% 
miR-203 80% 83% 89% 71% 81% 
miR-222 30% 17% 38% 13% 25% 
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Table 3.3. Average miR Expression Among the Molecular Subtypes of Breast Cancer. The 
table shows the average expression (relative to the expression in normal breast tissue ± SEM) 
of the regulatory miRs in each of the intrinsic subtypes of breast cancer. 
 Luminal A (n=36) Luminal B (n=13) HER2+(n=5) Basal-like (n=16) 
miR-29a 2.37±0.33 2.44±0.58 2.02±0.46 2.22±0.64 
miR-29b 7.39±1.24 7.95±1.62 4.85±1.46 8.93±2.72 
miR-29c 5.74±1.07 8.48±3.37 3.22±0.67 1.89±0.38 
miR-148a 3.56±0.50 3.41±0.86 2.77±0.60 3.66±0.81 
miR-148b 4.13±0.58 4.29±0.63 3.01±0.73 3.74±1.09 
miR-26a 1.77±0.19 1.69±0.33 1.35±0.48 1.13±0.38 
miR-26b 2.63±0.34 3.02±0.53 1.61±0.49 2.11±0.72 
miR-203 3.67±0.78 11.75±3.34 18.65±9.56 17.70±7.29 
miR-222 1.36±0.43 1.34±0.32 2.35±1.01 1.70±0.54 
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Table 3.4. Bayesian Analyses Show That Loss of miR Expression is Associated with 
Expression of Hypermethylation Defect in Primary Cancers. Threshold values for Bayesian 
analysis are as follows: miR-29a, 2.40; miR-29b, 14.00; miR-29c, 2.60; miR-148a, 2.70; 
miR-148b, 3.50; miR-26a, 1.30; miR-26b, 4.00; miR-203, 10.00; and miR-222, 0.76. 
 
 
 
 Sensitivity Specificity 
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
Correct 
Assignment
miR-29a 89% 58% 73% 80% 75% 
miR-29b 100% 43% 69% 100% 75% 
miR-29c 67% 43% 60% 50% 63% 
miR-148a 78% 71% 78% 71% 75% 
miR-148b 89% 57% 73% 80% 75% 
miR-26a 100% 57% 75% 100% 81% 
miR-26b 100% 43% 69% 100% 75% 
miR-203 78% 43% 64% 60% 63% 
miR-222 56% 86% 83% 60% 69% 
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Figure 3.1. Re-expression of Methylation-Sensitive Genes in Hypermethylator Breast Cancer 
Cell Lines Following Demethylating Treatment. (a) MDA-MB-453, BT549, and Hs578T 
cells were treated with 250 nM 5-aza for 7 days and real-time PCR was performed for 
CEACAM6, CST6, ESR1, and SCNN1A. (b) MDA-MB-453, BT549, and Hs578T cells were 
treated with 500 nM 5-aza for 7 days and real-time PCR was performed for CEACAM6, 
CST6, ESR1, and SCNN1A. The bars represent the fold-change in levels of expression for 
each gene and cell line relative to the untreated control cells (where RQ = 1). NS = not 
statistically significant, *p<0.05, **p<0.005, ***p<0.0005.  
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Figure 3.2. Demethylating Treatment with 5-Aza Sensitizes Hypermethylator Breast Cancer 
Cells to Chemotherapy. The blue lines represent breast cancer cells with no pretreatment, red 
lines represent cells pretreated with 250 nM 5-aza for 7 days, and green lines represent cells 
pretreated with 500 nM 5-aza for 7 days. Changes in chemotherapeutic sensitivity are shown 
as percentage of viable cells remaining (relative to untreated control cells) after 72 hrs of 
drug exposure for the indicated doses. (a) BT549 breast cancer cells exhibit increased DOX 
efficacy after 250 nM and 500 nM 5-aza pretreatment. (b) MDA-MB-453 breast cancer cells 
exhibit increased PAX efficacy after 500 nM 5-aza pretreatment. (c) Hs578T breast cancer 
cells exhibit increased 5-FU efficacy after 500 nM 5-aza pretreatment.  
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Figure 3.3. RNAi-mediated Knockdown of DNMT3b Results in Reduction in DNMT3b 
Protein Levels in Hypermethylator Breast Cancer Cell Lines. (a) Western blot analysis of 
DNMT3b protein levels in MDA-MB-453, BT549, and Hs578T cells. Actin levels are shown 
as a loading control.  (b) Quantification of DNMT3b protein levels relative to actin. (c) 
Western blot analysis of DNMT3b protein levels in MDA-MB-453, BT549, and Hs578T 
cells after RNAi-mediated knockdown of DNMT3b. Western blot analysis was performed by 
Dr. Ashley G. Rivenbark (Department of Biochemistry and Biophysics, UNC). Actin levels 
are shown as a loading control.  NS = not statistically significant. 
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Figure 3.4. RNAi-mediated Knockdown of DNMT3b Results in Re-expression of 
Methylation-Sensitive Genes in Hypermethylator Breast Cancer Cell Lines. Hypermethylator 
breast cancer cells re-express methylation-sensitive DNMT3b target genes after DNMT3b 
KD.  The blue bars represent real-time PCR results for wild-type cells, the red bars represent 
the results in scram-transfected cells and green bars represent the results in DNMT3b KD 
cells compared to wild-type control cells (where RQ = 1). (a) MDA-MB-453 breast cancer 
cells re-express CEACAM6, CST6, ESR1, and SCNN1A after DNMT3b KD. (b) BT549 
breast cancer cells re-express CEACAM6, CST6, ESR1, and SCNN1A after DNMT3b KD. (c) 
Hs578T breast cancer cells re-express CEACAM6, CST6, ESR1, and SCNN1A after DNMT3b 
KD.  *p<0.05, **p<0.005, ***p<0.0005.  
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Figure 3.5. RNAi-mediated Knockdown of DNMT3b Results in Demethylation of 
Methylation-Sensitive Genes in Hypermethylator Breast Cancer Cell Lines. Representative 
agarose gels of methylation-specific PCR (MSP) products corresponding to CST6, ESR1, and 
SCNN1A are shown. M = methylated MSP product, U = unmethylated MSP product.  The 
abbreviations are as follows: Con = no DNA control, WT = wild-type, KD = DNMT3b 
knockdown. (a) Changes in methylation status of CST6 in MDA-MB-453, Hs578T, and 
BT549 cells after DNMT3b knockdown. (b) Changes in methylation status of ESR1 in 
MDA-MB-453 and Hs578T cells after DNMT3b knockdown. (c) Changes in methylation 
status of SCNN1A in MDA-MB-453 and Hs578T cells after DNMT3b knockdown. 
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Figure 3.6. Hypermethylator Breast Cancer Cell Lines Exhibit Increased Sensitivity to 
Chemotherapeutic Drugs after DNMT3b Knockdown. The blue lines represent wild-type 
breast cancer cells, red lines represent cells transfected with scrambled control vector, and 
green lines represent cells after DNMT3b knockdown. Changes in chemotherapeutic 
sensitivity are shown as percentage of viable cells remaining (relative to wild-type control 
cells) after 72 hrs of drug exposure for the indicated doses. (a) BT549 breast cancer cells 
show increased DOX efficacy after DNMT3b knockdown. (b) MDA-MB-453 breast cancer 
cells show increased PAX efficacy after DNMT3b knockdown. (c) Hs578T breast cancer 
cells show increased 5-FU efficacy after DNMT3b knockdown.  
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Figure 3.7. Demethylating Treatment With 5-Aza Sensitizes Hypermethylator Breast Cancer 
Cells to Chemotherapy after DNMT3b Knockdown. The blue lines represent DNMT3b KD 
breast cancer cells with no pretreatment, red lines represent DNMT3b KD cells pretreated 
with 250 nM 5-aza for 7 days, and green lines represent DNMT3b KD cells pretreated with 
500 nM 5-aza for 7 days. Changes in chemotherapeutic sensitivity are shown as percentage 
of viable cells remaining (relative to untreated DNMT3b KD control cells) after 72 hrs of 
drug exposure for the indicated doses. (a) BT549 DNMT3b KD breast cancer cells show 
increased DOX efficacy after 250 nM and 500 nM 5-aza pretreatment. (b) Hs578T DNMT3b 
KD breast cancer cells show increased PAX efficacy after 500 nM 5-aza pretreatment. (c) 
MDA-MB-453 DNMT3b KD breast cancer cells show increased 5-FU efficacy after 500 nM 
5-aza pretreatment.  
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Figure 3.8. Comparison of Sensitizing Effects of Demethylating Treatment, DNMT3b 
Knockdown, and Combined Demethylating Treatment and DNMT3b Knockdown in 
Hypermethylator Breast Cancer Cells to Chemotherapy. The dark blue lines represent breast 
cancer cells with no pretreatment, red lines represent wild-type cells pretreated with 250 nM 
5-aza for 7 days, green lines represent wild-type cells pretreated with 500 nM 5-aza for 7 
days, purple lines represent DNMT3b KD breast cancer cells with no pretreatment, light blue 
lines represent DNMT3b KD cells pretreated with 250 nM 5-aza for 7 days, and orange lines 
represent DNMT3b KD cells pretreated with 500 nM 5-aza for 7 days. Changes in 
chemotherapeutic sensitivity are shown as percentage of viable cells remaining (relative to 
untreated control cells) after 72 hrs of drug exposure for the indicated doses. (a) MDA-MB-
453 breast cancer cells show increased DOX efficacy. (b) BT549 breast cancer cells show 
increased PAX efficacy. (c) Hs578T breast cancer cells show increased 5-FU efficacy.  
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Figure 3.9.  Differential miR Expression Among Hypermethylator and Non-Hypermethylator 
Breast Cancer Cell Lines. Red bars represent average miR expression among 
hypermethylator cell lines (n=10), and green bars represent average miR expression among 
non-hypermethylator cell lines (n=6). Comparison of the observed expression levels between 
hypermethylator cell lines and non-hypermethylator cell lines was accomplished using an 
unpaired t-test (two-tailed) and corresponding p values are given (NS – not significant). 
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Figure 3.10.  miR Expression Among Hypermethylator and Non-Hypermethylator Breast 
Cancer Cell Lines. (a-f) Analysis of miR expression among hypermethylator and non-
hypermethylator breast cancer cell lines. Hypermethylator cell lines are represented by red 
bars and non-hypermethylator cell lines are represented by green bars. The orange dashed 
line represents the optimal threshold value determined by Bayesian analysis for correct 
assignments related to methylation status of individual cell lines. Each real-time assay was 
performed in triplicate and error bars represent S.E.M. MDA-MB-231, MDA-MB-415, 
MDA-MB-435s, MDA-MB-436, and MDA-MB-453 cell line are designated 231, 415, 435s, 
436, and 453, respectively; SUM102, SUM149, and SUM185 cell lines are represented as 
102, 149, and 185, respectively; and HCC1937 is labeled 1937. (a) miR-29c expression, (b) 
miR-148a expression, (c) miR-148b expression, (d) miR-26a expression, (e) miR-26b 
expression, (f) miR-203 expression. 
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Figure 3.11. miR Expression Patterns and miR Scores for Hypermethylator and Non-
Hypermethylator Breast Cancer Cell Lines. Red boxes indicate a measured level of 
expression for an individual miR that is below the threshold value established through 
Bayesian analysis, and white boxes indicate a measured level of expression of an individual 
miR that is above the threshold value established through Bayesian analysis. The numbers at 
the bottom of each column indicate the miR score which represents a measure of the number 
of miRs expressed at diminished levels in an individual cell line. (a)  miR expression patterns 
and miR scores for hypermethylator breast cancer cell lines. (b)  miR expression patterns and 
miR scores for non-hypermethylator breast cancer cell lines. 
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Figure 3.12. miR Expression Patterns Correlate with Methylation-Sensitive Gene 
Expression Status and Promoter Methylation Status Among Breast Cancer Cell Lines. 
Correlation of miR expression patterns (miR score) with gene expression levels (based on 
RT-PCR) and promoter methylation status (based on methylation-sensitive PCR) for 
methylation-sensitive genes among hypermethylator and non-hypermethylator breast cancer 
cell lines. Scores were calculated for differentially expressed miRs (miR-29c, miR-148a, 
miR-148b, miR-26a, miR-26b, and miR-203) and for well-characterized methylation 
sensitive genes (CEACAM6, CDH1, CST6, ESR1, GNA11, MUC1, MYB, TFF3, and 
SCNNIA).  Methylation-sensitive gene expression scores and promoter methylation scores 
were taken from previous studies [150]. (a) Relationship between miR score and gene 
expression score among hypermethylator cell lines (red diamonds) and non-hypermethylator 
cell lines (green squares). (b)  Relationship between miR score and promoter methylation 
status among hypermethylator cell lines (red diamonds) and non-hypermethylator cell lines 
(green squares). 
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Figure 3.13. Co-regulation of miR Expression. Hypermethylator cell lines (red diamonds) 
and non-hypermethylator cell lines (green diamonds) demonstrate a statistically significant 
relationship between miR expression levels. The blue dashed line represents the linear 
regression trend line (p values are indicated). (a) Association of expression between miR-26a 
and miR-26b, (b) Association of expression between miR-148a and miR-26a, (c) Association 
of expression between miR-148a and miR-26b, (d) Association of expression between miR-
29c and miR-148a, (e) Association of expression between miR-148a and miR-148b, (f) 
Association of expression between miR-29c and miR-148b. 
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Figure 3.14. Changes in miR Expression Levels in Hypermethylator Breast Cancer Cell 
Lines After Pre-miR Transfection. Blue bars represent miR expression levels in untransfected 
control cells, red bars represent miR expression levels in cells transfected with non-target 
control oligomers, and green bars represent miR expression levels in cells after indicated pre-
miR transfections. (a) Hs578T breast cancer cells re-express miR-148b, miR-26b, and miR-
29c after pre-miR transfection. (b) HCC1937 breast cancer cells re-express miR-148b, miR-
26b, and miR-29c after pre-miR transfection. (c) SUM185 breast cancer cells re-express 
miR-148b, miR-26b, and miR-29c after pre-miR transfection. Each real-time assay was 
performed 3-6 times and error bars represent S.E.M. *p<0.05, **p<0.005, ***p<0.0005, 
compared to untransfected control cells (unpaired t-test). 
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Figure 3.15. Changes in miR Expression Levels in Non-Hypermethylator Breast Cancer Cell 
Lines after Antagomir Transfection. Blue bars represent miR expression levels in 
untransfected control cells, red bars represent miR expression levels in cells transfected with 
non-target control oligomers, and green bars represent miR expression levels in cells after 
indicated antagomir transfections. (a) BT20 breast cancer cells express diminished levels of 
miR-148b, miR-26b, and miR-29c after antagomir transfection. (b) MDA-MB-415 breast 
cancer cells express reduced levels of miR-148b, miR-26b, and miR-29c after antagomir 
transfection. (c) MDA-MB-468 breast cancer cells express reduced levels of miR-148b, miR-
26b, and miR-29c after antagomir transfection. Each real-time assay was performed 3-6 
times and error bars represent S.E.M. *p<0.05, **p<0.005, ***p<0.0005, compared to 
untransfected control cells (unpaired t-test). 
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Figure 3.16. Perturbation of Regulatory miR Expression affects DNMT3b Levels in 
Hypermethylator Cell Lines. Hypermethylator breast cancer cells (Hs578T, HCC1937, and 
SUM185) exhibit significant reduction in DNMT3b mRNA levels following pre-miR 
transfection for miR-148b, miR-26b, and miR-29c. Each real-time assay was performed 3-6 
times and error bars represent S.E.M. **p<0.005, ***p<0.0005, compared to untransfected 
control cells (unpaired t-test). 
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Figure 3.17. Perturbation of Regulatory miR Expression affects DNMT3b Levels in Non-
hypermethylator Cell Lines. Non-hypermethylator breast cancer cells (MDA-MB-468, MDA-
MB-415, and BT20) display significantly increased DNMT3b mRNA levels following 
transfection with antagomirs for miR-148b, miR-26b, and miR-29c. Each real-time assay was 
performed 3-6 times and error bars represent S.E.M. **p<0.005, ***p<0.0005, compared to 
untransfected control cells (unpaired t-test). 
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Figure 3.18. Gene Expression Patterns of Methylation-Sensitive Genes for Human Primary 
Breast Cancers. Red boxes indicate a measured level of expression for an individual gene 
that is below the median level of expression for the dataset, and white boxes indicate a 
measured level of expression of an individual gene that is above the median level of 
expression for the dataset. The numbers at the bottom of each column indicate the number of 
methylation sensitive genes expressed at diminished levels in an individual cancer. ‘B’ 
represents basal-like cancers, ‘H’ represents HER2+ cancers, LA represents luminal A 
cancers, and LB represents luminal B cancers. 
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Figure 3.19. Classification of Basal-like Breast Cancers into Hypermethylators and Non-
hypermethylators based on the Gene Expression Patterns of Methylation-Sensitive Genes. 
Red boxes indicate a measured level of expression for an individual gene that is below the 
median level of expression for the dataset, and white boxes indicate a measured level of 
expression of an individual gene that is above the median level of expression for the dataset. 
The numbers at the bottom of each column indicate the number of methylation sensitive 
genes expressed at diminished levels in an individual cancer.  
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Figure 3.20. miR Expression Patterns and miR Scores for Human Primary Breast Cancers. 
Red boxes indicate a level of expression for an individual miR below the median value, and 
white boxes indicate a level of expression of an individual miR that is above the median 
value for the dataset. The numbers at the bottom of each column indicate the miR score 
which represents a measure of the number of miRs expressed at diminished levels in an 
individual tumor. ‘B’ represents basal-like cancers, ‘H’ represents HER2+ cancers, LA 
represents luminal A cancers, and LB represents luminal B cancers. 
  
 0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
miR‐29a miR‐29b miR‐29c miR‐148a miR‐148b miR‐26a miR‐26b miR‐203 miR‐222
Av
er
ag
e 
M
ic
ro
RN
A
 E
xp
re
ss
io
n 
(R
Q
)
Hypermethylator
Non‐hypermethylator
p = 0.11
p
p = 0.73
p = 0.64 p = 0.74 = 0.03 p = 0.08
p = 0.03p = 0.35 p = 0.71
161 
 
162 
 
Figure 3.21. Differential miR Expression in Hypermethylator and Non-Hypermethylator 
Basal-Like Breast Cancers. (A) Red bars represent average miR expression among 
hypermethylator cancers (n=9), and green bars represent average miR expression among non-
hypermethylator cancers (n=7). Comparison of the observed expression levels between 
hypermethylator cancers and non-hypermethylator cancers was accomplished using an 
unpaired t-test (two-tailed) and corresponding p values are given (NS - not significant). 
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 Figure 3.22. Analysis of miR Expression Among Hypermethylator and Non-Hypermethylator 
Basal-like Breast Cancers. Hypermethylator cancers are represented by red bars and non-
hypermethylator cancers are represented by green bars. The orange dashed line represents the 
optimal threshold value determined by Bayesian analysis for correct assignments related to 
methylation status of individual cell lines. Each real-time assay was performed in triplicate 
and error bars represent S.E.M. (a) miR-29a expression, (b) miR-26a expression, (c) miR-
29b expression, (d) miR-26b expression, (e) miR-29c expression, (f) miR-148a expression, 
(g) miR-148b expression, (h) miR-203 expression, and (i) miR-222 expression. 
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 Figure 3.23. miR Expression Patterns and miR Scores for Hypermethylator and Non-
Hypermethylator Basal-Like Breast Cancers. Red boxes indicate a measured level of 
expression for an individual miR that is below the threshold value established through 
Bayesian analysis, and white boxes indicate a measured level of expression of an individual 
miR that is above the threshold value established through Bayesian analysis. The numbers at 
the bottom of each column indicate the miR score which represents a measure of the number 
of miRs expressed at diminished levels in an individual breast cancer.  
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Figure 3.24. miR Expression Patterns Correlate with Promoter Methylation Status among 
Basal-Like Breast Cancers. Correlation of miR expression patterns (miR score) with gene 
expression levels (based on RT-PCR) for methylation-sensitive genes among 
hypermethylator and non-hypermethylator basal-like breast cancers. Hypermethylator 
cancers are represented as red diamonds and non-hypermethylator cancers are represented as 
green diamonds.  
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Figure 3.25. miR Expression Patterns Classify Basal-Like Breast Cancers into Low 
Expresser and High Expresser Subsets. Low-expresser subset had low levels of expression of 
at least 6/9 miRs of interest for an individual breast cancer. High expresser subset includes 
the cancers with normal/high expression of at least 4/9 miRs of interest. Red boxes indicate a 
measured level of expression for an individual miR that is below the threshold value 
established through Bayesian analysis, and white boxes indicate a measured level of 
expression of an individual miR that is above the threshold value established through 
Bayesian analysis. The numbers at the bottom of each column indicate the miR score which 
represents a measure of the number of miRs expressed at diminished levels in an individual 
breast cancer.   
  
DISCUSSION 
 
Enhancement of Chemotherapeutic Efficacy in Hypermethylator Breast Cancer Cells 
by Targeting The Epigenome 
 The initiation, development, and progression of breast cancer reflects a multistep 
process that involves genetic and epigenetic changes resulting in activation of oncogenes and 
inactivation of tumor suppressor genes [77, 239-241]. Frequently observed genetic 
abnormalities in breast cancer include large-scale chromosomal deletions, sequence 
mutations (frameshift and point mutations), copy-number changes (including gene 
amplifications), and gene rearrangements (translocations). The understanding of these 
specific genetic alterations in breast cancer led to the development of targeted therapeutic 
approaches. Identification of HER2 amplification as a treatment target in approximately 30% 
of breast cancers led to the development of human monoclonal antibody, Herceptin 
(trastuzumab) [242-246]. Treatment with Herceptin significantly improves outcomes in 
HER2-amplified breast cancer patients [72, 247-249]. In contrast to gain-of-function 
oncogenic mutations, correction of loss-of-function tumor suppressor gene mutations through 
gene therapy has been largely unsuccessful. Epigenetic alterations also make substantial 
contributions to the regulation of gene expression [88, 92, 93] and have been established as 
an important mechanism contributing to breast carcinogenesis. A number of genes have been 
shown to be inactivated in breast cancer through methylation-dependent gene silencing, 
including cell cycle control genes (APC, RASSF1, RB, TFAP2A), tumor suppressor genes 
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(CST6, BRCA1, PRDM2), metastasis-associated genes (CDH1, CEACAM6, LGALS3BP), 
steroid receptor genes (ESR1, PGR, RARα), and many others [119, 120, 150, 250, 251]. The 
number of genes silenced by methylation in breast cancer, in association with the cellular 
activities in which they participate, suggests strongly that aberrant DNA methylation 
contributes to the biological and clinical behaviors of breast cancer. Aberrant DNA 
methylation and epigenetic silencing of gene expression are now well recognized as frequent 
and reversible (unlike genetic mutation) hallmarks of cancer [74, 79, 80, 92, 252], leading 
numerous investigators to suggest that cancer should be treated with “epigenetic therapy” 
[253-257]. In contrast to gene therapy, epigenetic therapy (demethylating treatment) alters 
gene expression patterns in breast cancer without complications from enhanced immune 
response to therapeutic DNA. The reversibility of epigenetic alterations makes them 
excellent targets for improving breast cancer outcomes [239, 258]. In addition, by targeting 
faulty epigenetic modification patterns, one can concurrently target multiple genes. The goal 
of such therapy is to effect changes in gene expression, including re-expression of silenced 
genes (like tumor suppressor genes), that alter the clinical behavior of the tumor or response 
of the tumor to chemotherapy. 
  In the current investigation, we tested the hypothesis that epigenetic therapy using 
very low (non-cytotoxic) doses of 5-aza would sensitize hypermethylator breast cancer cell 
lines (MDA-MB-453, BT549, and Hs578T) to the cytotoxic effects of standard 
chemotherapeutic drugs. The results clearly show increased efficacy of chemotherapeutic 
drugs against these cell lines following epigenetic therapy and the increase in efficacy was a 
function of dose and duration of exposure to the demethylating drug. To provide further 
evidence that the improved efficacy was a consequence of modulating the DNA methylation 
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machinery, we knocked down DNMT3b, which drives expression of hypermethylation defect 
in breast cancer cells [150]. Targeted inhibition of DNMT3b produced trends of enhanced 
chemosensitivity in each cell line comparable to that observed with pharmacological 
inhibition utilizing 5-aza. We employed three different cell lines and three chemotherapeutic 
drugs to eliminate the possibility that the effects were cell line or drug-specific. 5-aza-2’-
deoxycytidine (Decitabine) is FDA approved for clinical use in patients with myelodysplastic 
syndromes [258-260]. Thus, the possible use of sensitizing doses of 5-aza in conjunction 
with established chemotherapeutic regimens is very exciting.  
  In previous studies, mining of microarray-based expression data identified the 
hypermethylation defect-associated gene expression signature in primary sporadic invasive 
breast cancers [150]. We observed strong correspondence between expression of the 
hypermethylation defect and the basal-like sub-group of breast cancers [150]. Many basal-
like breast cancers express a hypermethylation defect characterized by silencing of numerous 
genes associated with DNMT3b protein overexpression. This observation strongly suggests 
that the unique characteristics of basal-like breast cancers (poor clinical outcomes, variable 
response to chemotherapy, and recurrence following chemotherapy) may be a direct 
consequence of methylation-dependent gene silencing associated with DNMT3b 
overexpression. This fundamental observation related to the basal-like breast cancers 
identifies the DNA methylation machinery (and specifically DNMT3b) as a novel target for 
development of new treatment regimens for these deadly breast cancers. Neoplasms that 
express this hypermethylation defect may exhibit poor response to chemotherapeutic 
treatment if the targets of methylation-dependent gene silencing encode proteins that function 
in DNA repair, apoptosis, or other pathways required for drug response. Therefore, 
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demethylating treatment of basal-like breast cancers may sensitize these neoplasms to 
standard drug regimens, resulting in increased chemotherapeutic efficacy. Since these tumors 
lack the expression of hormone receptors and HER2 amplification, patients with these tumors 
do not derive benefit from targeted therapies like tamoxifen (targeting ER) and trastuzumab 
(targeting HER2). The poor long-term outcomes for basal-like breast cancers are likely due 
to high relapse rate [173, 174, 261, 262]. It has been shown that prognosis correlates with 
pathological complete response and that if initially patients do not achieve complete 
response, they are more likely to have an early relapse, frequently leading to death of the 
patient [173, 174]. Thus, enhancement in the efficacy of chemotherapeutics to achieve higher 
response rate by making these neoplasms more sensitive may lead to higher pathological 
complete response and consequently better long-term outcomes. Lack of identification of 
druggable targets in basal-like breast cancers, poor prognosis, and association of positive 
clinical outcome with pathological complete response in response to chemotherapy makes 
the assessment of new therapeutic strategies to be of utmost significance. The results of the 
current study suggest strongly that combined epigenetic and cytotoxic chemotherapy should 
be evaluated for treatment of basal-like breast cancer.  
   In these studies, we provide evidence that targeted and pharmacological inhibition of 
DNMT3b augments the efficacy of chemotherapeutic drugs. This observation has the 
potential of becoming a useful therapeutic modality. Increasing the efficacy can be employed 
to benefit the patients in at least two different ways. First, increasing the efficacy of a certain 
fixed dose may increase the benefits of chemotherapy without associated increases in toxic 
side-effects. Secondly, a lower dose of chemotherapeutic drug may be used to achieve a 
certain fixed therapeutic effect, but with diminished side effects. These studies provide proof-
183 
 
of-concept that sensitizing pretreatment followed by a standard chemotherapeutic regimen 
improves cell killing in breast cancer. Since cancer results from a combination of genetic and 
epigenetic alterations, it can be anticipated that a combination of epigenetic and 
genetic/chemotherapeutic therapy will be beneficial.  However, these results also suggest the 
combination therapy employing other cytotoxic drugs/classes e.g., cyclophosphamide, 
carboplatin, methotrexate may also sensitize the cancers to chemotherapy.  
 Our studies provide proof-of-principle for utilizing epigenetic therapy as a 
chemosensitizer in treatment of breast cancer. Nevertheless, further laboratory studies and 
clinical trials are needed to fully establish the therapeutic efficacy of agents that can modify 
DNA methylation. 5-aza-2’deoxycytidine and its parent compound, 5-azacytidine 
demonstrate demethylating activity [258, 263, 264] and have been widely used in cell culture 
models to reverse DNA hypermethylation leading to restoration of silenced gene expression 
[265, 266]. Being cytidine analogs, these agents become incorporated into DNA during DNA 
replication, are trapped and inactivated as covalent protein-DNA adducts. Sequestration of 
these agents leads to depletion of cellular DNA methyltransferase activity during DNA 
synthesis resulting in reduced methylation (demethylation) of newly synthesized DNA [265, 
267]. 5-aza-2’deoxycytidine exhibits favorable properties in comparison with 5-azacytidine 
that includes greater DNA methylation inhibition and greater anti-cancer activity at 
equivalent doses in experimental models [263] but the side effects and potential risks hinder 
its clinical application. These risks include effects relating to bone marrow suppression like 
neutropenia [268], mutagenesis [269], and tumorigenesis [270]. It is also highly cytotoxic at 
higher doses and has a short half-life owing to degradation by hydrolytic cleavage and 
deamination by cytidine deaminase. For 5-aza to progress as a chemosensitizer, these side 
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effects and toxicity issues have to be addressed. The neutropenia induced by demethylating 
agent could render a patient unfit for chemotherapy, contradicting the purpose of 
administering a demethylating agent. The experimental design utilizing low doses of 5-aza in 
our studies was employed to keep the toxic and cytotoxic effects to minimum. In fact, we did 
not see any cytotoxic effects with 5-aza in our cell culture model. Further studies need to be 
conducted focusing on pharmacodynamic endpoints like optimal biologic dose rather than 
maximal tolerated dose. 5-aza is not very stable and cannot be orally administered, therefore 
it may need to be given as daily treatments. The resulting frequent visits by the patient to 
hospital will impact quality of life and have cost implications in addition to patient 
inconvenience. Therefore, the nucleoside analogues that have longer half-life and/or can be 
orally administered may offer some advantages over 5-aza. A less toxic derivative of 5-
azacytidine, Zebularine has been recently developed [258, 267]. Zebularine can be given 
orally, but it has variable bioavailability resulting in significant demethylation relative to 
dose in mice [271] and relatively low demethylation in monkeys [272].   
 The nucleoside analogues require incorporation into DNA and are S-phase specific. 
Hence, the majority of cancer cells must pass through S-phase while the drug is present for it 
to effectively demethylate the DNA. The majority of toxic effects associated with these 
agents have been associated with the formation of covalent adducts between DNA and 
trapped DNA methyltransferases [258]. The inherent toxic effects of nucleoside analogues 
resulted in identification and development of non-nucleoside compounds that target DNA 
methyltransferases without getting incorporated into DNA and are mostly catalytic site 
inhibitors [267]. Since these substances directly block DNA methyltransferase activity, they 
do not display toxicity caused by the covalent trapping of the enzyme seen with nucleoside 
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analogues. One of these non-nucleoside compounds with DNMT inhibitor activity is 
epigallocatechin-3-gallate (EGCG), the main polyphenol compound in green tea [273]. 
EGCG inhibits DNA methyltransferase activity in human cancer cell lines by blocking the 
active site of human DNMT1 [274]. However, EGCG also generates significant amount of 
hydrogen peroxide resulting in toxicity due to the effects of hydrogen peroxide as an 
oxidizing agent [275].   Other compounds include the antiarrythmic drug procainamide and 
local anesthetic procaine that exhibit demethylating activity. Procainamide reverses 
hypermethylation in LNCaP (prostate cancer cell line) in vitro as well as in LNCaP xenograft 
tumors in vivo [276]. Procaine directly binds to CpG-rich sequences in DNA, inhibiting the 
interaction between DNA methyltransferases and their target CpGs [277]. However, Procaine 
exhibits demethylating activity at very high doses and the activity is highly variable across a 
panel of cell lines [258]. Since non-nucleoside analogues are not incorporated into DNA, it 
may suggest that these compounds are less toxic. However, it has been reported that non-
nucleoside DNMT inhibitors are not any less toxic than nucleoside inhibitors, but are also 
less potent and less effective as demethylating agents compared to nucleoside inhibitors 
[265]. Other approaches to target DNA methylation machinery include development of small 
molecule inhibitor to target DNA methyltransferases. RG108, a small molecule inhibitor of 
human DNA methyltransferases have been developed that blocks the active site of the 
enzymes and thus inhibits their catalytic activity [278]. The inhibitory mechanism of RG108 
is specific for DNA methyltransferases; therefore it targets DNMT1, DNMT3a, and 
DNMT3b. Hence, RG108 emerges as an attractive target for functioning as a lead compound 
for developing inhibitors specific to DNMT1, DNMT3a, and DNMT3b [258]. The current 
studies also clearly identify DNMT3b as a potential therapeutic target and our RNAi 
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experiments strongly suggests the potential value of development of true targeted therapy 
using a small molecule inhibitor of DNMT3b. Small molecule inhibitors may be orally 
available and express greater target specificity eliminating unwanted side effects associated 
with broad-spectrum DNMT inhibitors like 5-aza.  
 The observations made in our studies also suggest that this therapeutic strategy 
(combining epigenetic treatment with conventional chemotherapy) may find utility in 
malignancies from other tissue types with well-defined or not so well-defined methylator 
phenotypes.  In our studies, we employed a period of demethylation treatment and used this 
period as a window for sensitization to chemotherapy. Published investigations show reversal 
of resistance to chemotherapeutic drugs in human xenograft models as a result of 
pretreatment with low doses of 5-aza 6-12 days prior to administration of chemotherapeutic 
drugs [279]. This reversal was associated with epigenetic re-activation of pro-apoptotic genes 
[258, 279]. More interestingly, this effect was abrogated if 5-aza was given concurrently with 
the cytotoxic drugs or after the cytotoxic therapy [279]. In another example, a randomized 
phase II study of the combination of 5-aza and carboplatin in relapsed ovarian cancer is 
currently underway [267, 280]. Based on results of the phase I trial,  a dose/schedule for the  
phase II trial reflects demethylating treatment with 5-aza (day1) followed by carboplatin (day 
8) and the repetition of this cycle every 28 days is recommended [280].  These observations 
strongly support our conclusion that demethylating pre-treatment sensitizes cancer cells to 
chemotherapeutic drugs. While additional investigations are needed to fully comprehend the 
possibilities associated with targeting DNMT3b in basal-like breast cancer (and other 
cancers), this observation of increased sensitivity to chemotherapeutics as a result of 
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modulation of DNA methylation machinery (more specifically DNMT3b) may present new 
options and targets to develop new treatment strategies. 
 
Loss of Post-Transcriptional Regulation of DNMT3b by Regulatory miRs Drives The 
DNMT3b-mediated Hypermethylation Defect in Breast Cancer 
Epigenetic changes significantly contribute to the normal regulation of gene 
expression and when dysregulated can significantly contribute to carcinogenesis [75, 76]. 
Aberrant epigenetic silencing of tumor suppressor genes and other negative mediators of cell 
proliferation have been documented in the development and progression of breast cancer [74, 
118, 129]. The CpG island methylator phenotype (or CIMP) represents a major epigenetic 
mechanism of colorectal carcinogenesis that has also been recognized in cancers affecting 
other tissues [134, 140, 143]. We have identified a hypermethylation defect in a subset of 
human breast cancer cell lines and primary breast cancers that is characterized by DNMT 
hyperactivity, overexpression of DNMT3b, and concurrent methylation-dependent silencing 
of numerous genes (including CDH1, CEACAM6, CST6, ESR1, GNA11, MYB, MUC1, 
SCNN1A, and TFF) [150].  Mining of microarray-based expression data identified a strong 
cluster of primary breast cancers that display a gene expression signature associated with the 
hypermethylation defect [150]. A strong association was established between the expression 
of the hypermethylation defect signature and the basal-like molecular subtype of breast 
cancers [150]. Basal-like breast cancers are typically classified as triple-negative, reflecting 
lack expression of estrogen and progesterone receptors (ER-/PR-), and absence of HER2 
gene amplification (HER2-) [281, 282]. Hence, patients with basal-like breast cancer are not 
responsive to targeted therapies like tamoxifen (targets ER) and trastuzumab (targets HER2) 
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[244, 283]. The poor prognosis associated with basal-like breast cancer and lack of druggable 
targets makes the fundamental observation of the co-segregation of the hypermethylation 
defect with basal-like breast cancer to be of utmost significance. Our observations suggest 
strongly that the DNA methylation machinery (and specifically DNMT3b) represent 
new/novel molecular targets for development of new drugs and treatment strategies for basal-
like breast cancer. 
In these studies, our goal was to elucidate the molecular mechanism accounting for 
overexpression of DNMT3b in hypermethylator breast cancer cell lines and hypermethylator 
breast cancers. Recent studies link miRs to the post-transcriptional regulation of DNMT3b 
expression in various tissues. Loss of expression of members of miR-29 family and 
overexpression of DNMT3b has been shown in lung cancer [223] and acute myeloid 
leukemia [224]. Likewise, there  is evidence supporting the negative regulation of DNMT3b 
by miR-148a and miR-148b in cell lines of multiple origins [225]. The results of the present 
study strongly suggest that loss of regulatory miR expression contributes to DNMT3b 
overexpression that characterizes the hypermethylation defect seen in breast cancer. In the 
breast cancer cell line model, this evidence includes: (i) differential expression of regulatory 
miRs between hypermethylator and non-hypermethylator cell lines, (ii) significantly 
diminished expression of miR-29c, miR-148a, miR-148b, miR-26a, miR-26b, and miR-203 
among hypermethylator breast cancer cell lines, (iii) pre-miR-mediated re-expression of 
miR-148b, miR-26b, or miR-29c in hypermethylator breast cancer cell lines (Hs578T, 
HCC1937, and SUM185) produces reduced DNMT3b mRNA levels, and (iv) antagomir-
mediated knockdown of miR-148b, miR-26b, or miR-29c in non-hypermethylator breast 
cancer cell lines (MDA-MB-468, MDA-MB-415, and BT20) leads to increased DNMT3b 
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mRNA levels. In primary tumors, we observed that (a) significantly reduced expression of 
miR-29c distinguished basal-like cancers from other subtypes of the primary breast tumors, 
(b) miR expression patterns revealed two groups among the basal-like breast cancers 
corresponding to diminished expression and normal levels of expression, (c) 7/9 
hypermethylators among basal-like tumors correspond to the group that has diminished 
expression of regulatory miRs. These findings strongly suggest that: (i) post-transcriptional 
regulation of DNMT3b is combinatorial, involving multiple miR species, (ii) diminished 
expression of regulatory miRs contributes to DNMT3b overexpression, (iii) re-expression of 
regulatory miRs results in reduced DNMT3b mRNA levels in hypermethylator breast cancer 
cell lines, and (iv) down-regulation of regulatory miRs results in increased DNMT3b mRNA 
levels in non-hypermethylator breast cancer cell lines. The observed loss of regulatory miRs 
in expression of the pro-cancerogenic hypermethylation defect suggests that these miRs 
possess a tumor suppressor-like function in breast, similar to other tissues [223-225].  
miRs are predicted to post-transcriptionally regulate more that 60% of all protein-
encoding genes in mammals and contribute to almost every cellular process, normal and 
pathological [188]. miRs have been recently been established as key players in 
carcinogenesis, with functions that can be oncogenic or tumor suppressor-like [187]. Our 
results suggest loss of combinations of miR-29c, miR-148a, miR-148b, miR-26a, miR-26b, 
and miR-203 is associated with expression of the hypermethylation defect in breast cancer 
cell lines, consistent with the idea that these miRs function as negative mediators of the 
neoplastic phenotype. We have also observed a significant concordance between the 
hypermethylators among basal-like breast cancers and the group of primary cancers that has 
diminished expression of regulatory miRs. Diminished levels of these miRs have been 
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documented in various forms of cancer, supporting the suggestion that these miRs possess 
tumor suppressor-like function. miR-29a and miR-29b are shown to be down-regulated in 
chronic lymphocytic leukemia, acute myeloid leukemia, lung cancers, cholangiocarcinoma, 
and prostate cancer [223, 237, 284-287]. Reduced expression of miR-26a occurs in 
hepatocellular carcinoma, oral squamous cell carcinoma, bladder cancer, thyroid anaplastic 
carcinoma, Burkitt’s lymphoma, acute myeloid leukemia, papillary carcinoma, prostate 
cancer, and breast cancer [188, 288, 289]. miR-26b expression is diminished in Hodgkin’s 
lymphoma, oral squamous cell carcinoma, and prostate cancers [289]. miR-29c expression is 
depressed in nasopharyngeal carcinomas, bladder tumors, chronic lymphocytic leukemia, 
acute myeloid leukemia, lung cancers, cholangiocarcinoma, esophageal squamous cell 
carcinoma and pancreatic ductal adenocarcinoma [188, 284, 288-290]. miR-148a is down-
regulated in breast cancers, papillary thyroid carcinoma, pancreatic ductal adenocarcinoma, 
prostate cancer, colorectal adenocarcinoma [288, 289]. miR-148b is expressed at reduced 
levels in oral squamous cell carcinoma, papillary thyroid carcinoma, prostate cancer, 
colorectal adenocarcinoma, pancreatic ductal adenocarcinoma [289]. miR-203 levels are 
diminished in oral squamous cell carcinoma, chronic myeloid leukemia, hepatocellular 
adenomas, esophageal squamous cell carcinoma [288, 289]. These studies from the literature 
document loss or diminished expression of these regulatory miRs in various forms of cancer, 
including breast in some cases.  
   Several molecular mechanisms contribute to miR dysregulation in cancer, including 
genetic abnormalities (such as chromosomal rearrangement, deletion, amplification, or 
sequence mutations) and epigenetic changes (methylation-dependent silencing of miR 
expression or alterations in the miRNA biogenesis machinery) [188]. Numerous miR genes 
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(>50%) are positioned within or close to chromosomal fragile sites and other genomic 
regions associated with cancer [188]. Genetic alterations involving these chromosomal 
regions result in dramatic alteration of miR expression levels [188]. Likewise, numerous 
studies report promoter hypermethylation as an important mechanism leading to loss of miR 
expression in cancer [187]. Loss of miR-203 expression is associated with fragile site on 
chromosome 14q32 [291], as well as through promoter hypermethylation in hematopoietic 
malignancies [291, 292]. miR-148a and miR148b are also susceptible to methylation-
dependent silencing in cancer [187]. We found miR-203 to be significantly co-regulated with 
miR148a and miR-148b, suggesting the possibility of a common epigenetic mechanism 
accounting for their diminished expression in hypermethylator cell lines. These examples 
from the literature suggest that loss of regulatory miR expression leading to DNMT3b 
dysregulation could be the result of genetic or epigenetic mechanisms.  
Numerous studies have established that miRs exhibit a unique and different 
expression in cancer tissues compared to normal tissues suggesting that miRs have a role in 
defining the molecular and pathological profiles of cancers including breast cancer [214, 216, 
238]. miRs expression profiles have shown that miRs are more efficient in differentiating 
between normal and cancer tissues, and are better at classifying poorly differentiated tissues 
[188, 293]. miRs are relatively stable and are resistant to RNAse degradation, most likely due 
to their small size [294-296]. They are highly stable in tissue sections and can be isolated and 
quantified from FFPE tissues. In addition, investigations have found that real-time PCR data 
and microarray data obtained from routinely processed FFPE tissues and/or frozen for 10 
years were reliable, reproducible, and consistent with data from fresh frozen samples [297, 
298].  These features and observations make miRs excellent biomarkers for cancer detection 
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and classification in terms of tissue of origin, stage, and other pathological features. 
Furthermore, the techniques of miR detection are now sufficiently sensitive to analyze miRs 
in a few nanograms of total RNA making miRs even more attractive candidates as 
biomarkers. Our studies indicate that loss of regulatory miRs is associated with expression of 
hypermethylation defect. We also observed that there exists substantial overlap between the 
expression of hypermethylation defect and basal-like subtype of breast cancers. These 
observations suggest that miRs can be used as potential biomarkers for the detection of the 
subset of primary breast cancers that express the hypermethylation defect. We have also 
shown that use of epigenetic treatment to alter the methylation status of breast cancers makes 
these cancers more sensitive to standard chemotherapeutic treatment. In current studies, we 
observed changes in DNMT3b levels with transient transfection of breast cancer cell lines 
with pre-miRs or with antagomirs. These findings suggest that modulating (re-expressing) 
levels of miRNAs that are deregulated resulting in DNMT3b overexpression and expression 
of hypermethylation defect in breast cancer may be significant to the outcomes of these 
cancers. These regulatory miRs represent potentially useful therapeutic ‘agents’ to amend the 
methylation machinery in hypermethylator breast cancers. Pre-treatment with these miRs 
may sensitize hypermethylator cancers to standard chemotherapy similar to our findings that 
demonstrate sensitization of hypermethylator breast cancer following treatment with 5-aza 
and/or DNMT3b knockdown. Several methods exist that can be employed to increase the 
expression of the miRs whose loss is associated with expression of the hypermethylation 
defect. This can be achieved by introducing a short synthetic duplex RNA molecule that is 
loaded onto RISC or by viral or liposomal delivery methods aimed at inducing the expression 
of pre-miRs [214, 299, 300]. Synthetic miRNAs include siRNA-like oligonucleotides as well 
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as chemically modified oligonucleotides. Studies aimed at facilitating alterations in the levels 
of miRs have the advantage that a lot of fundamental work in the field of delivery of siRNA 
and antisense molecules can be directly exploited. Although siRNA delivery has paved the 
way for potential use of miRs as therapeutic agents, it has its own challenges, such as 
developing ways to steer delivery to cancer cells, (possibly by antibody-mediated targeting of 
cancer-specific antigens), short life of the oligonucleotides necessitating repetitive 
administration and so on [214]. Nevertheless, miRs exhibit great potential to contribute to the 
future management of breast cancers among other cancers.  
 
Targeting the Epigenome in Basal-like Breast Cancer: Implications and Potential 
Impact in Prevention and Treatment 
The natural history of breast cancer development has long been recognized to 
progress from atypical ductal hyperplasia to ductal carcinoma in situ (DCIS), and then 
evolution of this pre-invasive lesion into invasive breast cancer that can ultimately develop 
into metastatic disease [301].  All of these stages represent a complex and multidimensional 
process of initiation, development, and progression of breast cancer. Intervention at any of 
these stages has the potential to significantly disrupt the natural history of disease and affect 
the outcome. For example, DCIS represents a commonly diagnosed breast lesion that 
accounts for 25% of breast neoplasms diagnosed in the United States and ~55,000 new cases 
each year [1, 302].  It is by definition non-invasive, but can vary from low-grade (and not life 
threatening) to high-grade lesions that may contain invasive elements and represents a risk 
factor for development of invasive breast cancer [303].  Consistent with natural history of 
disease, the incidence of DCIS increases with age in parallel with the incidence of invasive 
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breast cancer and many invasive breast cancers are associated with adjacent DCIS lesions. In 
the last decade, invasive breast cancers have been characterized using gene expression 
analysis and classified into several molecular subtypes that have implications for treatment 
and long-term survival [7, 58, 59, 304, 305]. More recently, analyses of gene expression 
patterns in pre-invasive breast cancers has identified similar molecular subtypes [306-311]. 
There exists a strong correspondence between molecular subtypes of pre-invasive and 
invasive cancers and this overlap is supported by the observation of basal-like DCIS in 
patients with basal-like breast cancer [309]. Numerous lines of evidence also suggest that 
breast cancers may develop through field cancerization, including significant observations 
made in patients with pre-invasive breast neoplasms.  Several studies have noted that the 
width of the surgical margin is directly associated with the risk of local recurrence (or 
development of invasive breast cancer) following breast conserving surgery for DCIS [302, 
303]. Likewise, whole-breast radiation therapy has been shown to significantly reduce the 
risk of development of invasive breast cancer following breast conserving surgery for DCIS 
[302]. Molecular evidence for field cancerization in the breast includes the observation of 
both genetic and epigenetic alterations in otherwise normal appearing breast epithelium.  
Genomic instability in the form of allelic imbalances have been characterized in 
histologically normal breast tissue adjacent to invasive breast cancers, suggesting that these 
genetic alterations occur early in breast carcinogenesis [312]. Likewise, numerous epigenetic 
alterations have been identified in histologically normal breast epithelium adjacent to 
invasive breast cancers, including promoter methylation-dependent silencing of CDH1, 
RASSF1A, RARα, APC, and others [313-316]. Likewise, epigenetic silencing of various 
genes has been shown in pre-neoplastic (atypical ductular hyperplasia) and pre-invasive 
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DCIS lesions [128, 317]. Given the linkage between basal-like breast cancers and expression 
of the hypermethylation defect, loss of regulatory miR expression leading to DNMT3b 
overexpression may represent a very early and significant molecular alteration during the 
natural history of breast carcinogenesis.  This observation paves the way for the potential role 
of miRs as diagnostic markers for detecting hypermethylation in very early/pre-invasive 
breast cancers. The loss of regulatory miRs in pre-invasive lesions leading to the 
establishment of the hypermethylation defect (with DNMT3b overexpression) may suggest 
that these alterations determine the basal-like molecular subtype of breast cancer. On the 
other hand, loss of miRs that regulate DNMT3b detected at a relatively advanced stage of 
breast cancer indicate that these miRs drive the basal-like molecular subtype of breast cancer. 
Early detection of these lesions creates the potential to identify patients for epigenetic 
therapies.  Presence of epigenetic changes before cancer appears/becomes invasive not only 
highlights epigenetic changes as seminal events in breast cancer initiation but also represents 
a potential target for chemoprevention. Treatment with demethylating agents and/or 
DNMT3b small molecule inhibitor can potentially halt the progression of disease and 
positively influence the outcome. Though in its infancy, the emerging concept of circulatory 
miRs is a great area of interest. Once, the high risk patients are identified (and/or treated with 
epigenetic therapy), circulating miRs provide non-invasive biomarkers for surveillance to 
determine if there is a need for continuing the prophylactic treatment or not. Likewise, after 
treatment, miR expression patterns associated with DNMT3b overexpression and 
hypermethylation defect can be used as surrogate endpoints for prognostic purposes to detect 
relapse and to monitor disease activity and response to therapy. Once the dose and schedule 
of epigenetic treatments is optimized so as to minimize toxicity, there is a possibility of using 
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these agents as maintenance therapies to prevent relapse following chemotherapy or even 
radiotherapy.  
 Restoration of the regulatory miRs by themselves is another attractive approach to 
correct the miR dysregulation that results in DNMT3b overexpression and hypermethylation 
defect. The expression patterns as well as promoter methylation status of methylation-
sensitive genes that are established targets of DNMT3b can be used as endpoints to regulate 
the therapy aimed at re-expression of the regulatory miRs. However, development of the 
miRs as diagnostic, therapeutic, and prognostic targets comes with lots of challenges and 
obstacles. Development of in vivo organ-specific delivery systems is very important. Since, 
the miRs are functionally very different based on the target organ, it will be imperative to 
develop a tissue-specific delivery system to prevent off-target effects and toxicity. 
Chemotherapy continues to be the mainstay of treatment for most of the breast cancers, 
especially in basal-like breast cancers. It is now known that miRs regulate multiple biological 
processes, it is conceivable that re-expressing regulatory miRs may alter drug response in 
multiple ways and not just by altering the epigenetic signature. Therefore, further studies are 
required before miR biology can move to clinical application in cancer. The translation of the 
observations made in our studies from bench to bedside remains a work in progress. In 
addition, further independent studies of miRs and their role in establishing hypermethylation 
effects in breast cancer will be helpful to validate and identify the most relevant miRs for this 
purpose. To fully understand and characterize the linkage between miR dysregulation and 
DNMT3b overexpression, it is imperative that all human miRs are known, identified and 
characterized fully including the features like functional targets of miRs and the phenotypic 
changes associated with their manipulation. In addition, the standardization of techniques for 
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miR analysis is necessary. However, miRs have shown a great potential in a relatively short 
time since their discovery, and seem to provide a promising and exciting basis for future 
studies. 
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